<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Epilepsia</journal-id>
<journal-id journal-id-type="iso-abbrev">Epilepsia</journal-id>
<journal-id journal-id-type="doi">10.1111/(ISSN)1528-1167</journal-id>
<journal-id journal-id-type="publisher-id">EPI</journal-id>
<journal-title-group>
<journal-title>Epilepsia</journal-title>
</journal-title-group>
<issn pub-type="ppub">0013-9580</issn>
<issn pub-type="epub">1528-1167</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30977115</article-id>
<article-id pub-id-type="pmc">6519005</article-id>
<article-id pub-id-type="doi">10.1111/epi.14722</article-id>
<article-id pub-id-type="publisher-id">EPI14722</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Full‐length Original Research</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Full‐length Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Epilepsy and seizures in young people with 22q11.2 deletion syndrome: Prevalence and links with other neurodevelopmental disorders</article-title>
<alt-title alt-title-type="left-running-head">EATON et al.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" id="epi14722-cr-0001">
<name>
<surname>Eaton</surname>
<given-names>Christopher B.</given-names>
</name>
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6739-1999</contrib-id>
<xref ref-type="aff" rid="epi14722-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="epi14722-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="epi14722-cr-0002">
<name>
<surname>Thomas</surname>
<given-names>Rhys H.</given-names>
</name>
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2062-8623</contrib-id>
<xref ref-type="aff" rid="epi14722-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="epi14722-aff-0003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="epi14722-cr-0003">
<name>
<surname>Hamandi</surname>
<given-names>Khalid</given-names>
</name>
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7116-262X</contrib-id>
<xref ref-type="aff" rid="epi14722-aff-0004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="epi14722-cr-0004">
<name>
<surname>Payne</surname>
<given-names>Gareth C.</given-names>
</name>
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5187-5323</contrib-id>
<xref ref-type="aff" rid="epi14722-aff-0005">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="epi14722-cr-0005">
<name>
<surname>Kerr</surname>
<given-names>Michael P.</given-names>
</name>
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8533-336X</contrib-id>
<xref ref-type="aff" rid="epi14722-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="epi14722-cr-0006">
<name>
<surname>Linden</surname>
<given-names>David E. J.</given-names>
</name>
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5638-9292</contrib-id>
<xref ref-type="aff" rid="epi14722-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="epi14722-aff-0006">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="epi14722-cr-0007">
<name>
<surname>Owen</surname>
<given-names>Michael J.</given-names>
</name>
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4798-0862</contrib-id>
<xref ref-type="aff" rid="epi14722-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="epi14722-cr-0008">
<name>
<surname>Cunningham</surname>
<given-names>Adam C.</given-names>
</name>
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9791-7813</contrib-id>
<xref ref-type="aff" rid="epi14722-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="epi14722-cr-0009">
<name>
<surname>Bartsch</surname>
<given-names>Ullrich</given-names>
</name>
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2213-8989</contrib-id>
<xref ref-type="aff" rid="epi14722-aff-0007">
<sup>7</sup>
</xref>
<xref ref-type="aff" rid="epi14722-aff-0008">
<sup>8</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="epi14722-cr-0010">
<name>
<surname>Struik</surname>
<given-names>Siske S.</given-names>
</name>
<xref ref-type="aff" rid="epi14722-aff-0009">
<sup>9</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" id="epi14722-cr-0011">
<name>
<surname>van den Bree</surname>
<given-names>Marianne B. M.</given-names>
</name>
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4426-3254</contrib-id>
<address>
<email>vandenbreemb@cardiff.ac.uk</email>
</address>
<xref ref-type="aff" rid="epi14722-aff-0001">
<sup>1</sup>
</xref>
</contrib>
</contrib-group>
<aff id="epi14722-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Medical Research Council Centre for Neuropsychiatric Genetics and Genomics</named-content>
<named-content content-type="organisation-division">Division of Psychological Medicine and Clinical Neurosciences</named-content>
<institution>Cardiff University School of Medicine</institution>
<named-content content-type="city">Cardiff</named-content>
<country country="GB">UK</country>
</aff>
<aff id="epi14722-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Cerebra Centre for Neurodevelopmental Disorders</named-content>
<named-content content-type="organisation-division">School of Psychology</named-content>
<institution>University of Birmingham</institution>
<named-content content-type="city">Birmingham</named-content>
<country country="GB">UK</country>
</aff>
<aff id="epi14722-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Institute of Neuroscience</named-content>
<institution>Newcastle University</institution>
<named-content content-type="city">Newcastle‐upon‐Tyne</named-content>
<country country="GB">UK</country>
</aff>
<aff id="epi14722-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">The Epilepsy Unit</named-content>
<institution>University Hospital of Wales</institution>
<named-content content-type="city">Cardiff</named-content>
<country country="GB">UK</country>
</aff>
<aff id="epi14722-aff-0005">
<label><sup>5</sup></label>
<institution>Betsi Cadwaladr University Health Board</institution>
<named-content content-type="country-part">Wales</named-content>
<country country="GB">UK</country>
</aff>
<aff id="epi14722-aff-0006">
<label><sup>6</sup></label>
<named-content content-type="organisation-division">School for Mental Health and Neuroscience</named-content>
<institution>Faculty of Health</institution>
<institution>Medicine and Life Sciences</institution>
<institution>Maastricht University</institution>
<named-content content-type="city">Maastricht</named-content>
<country country="NL">The Netherlands</country>
</aff>
<aff id="epi14722-aff-0007">
<label><sup>7</sup></label>
<named-content content-type="organisation-division">School of Physiology, Pharmacology and Neuroscience</named-content>
<institution>University of Bristol</institution>
<named-content content-type="city">Bristol</named-content>
<country country="GB">UK</country>
</aff>
<aff id="epi14722-aff-0008">
<label><sup>8</sup></label>
<institution>Lilly UK Erl Wood Manor</institution>
<named-content content-type="city">Surrey</named-content>
<country country="GB">UK</country>
</aff>
<aff id="epi14722-aff-0009">
<label><sup>9</sup></label>
<named-content content-type="organisation-division">Immunodeficiency Centre for Wales</named-content>
<institution>University Hospital of Wales</institution>
<named-content content-type="city">Cardiff</named-content>
<country country="GB">UK</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break></break>
Marianne B. M. van den Bree, Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University School of Medicine, Cardiff, UK.<break></break>
Email: <email>vandenbreemb@cardiff.ac.uk</email><break></break></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>11</day>
<month>4</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<month>5</month>
<year>2019</year>
</pub-date>
<volume>60</volume>
<issue>5</issue>
<issue-id pub-id-type="doi">10.1111/epi.2019.60.issue-5</issue-id>
<fpage>818</fpage>
<lpage>829</lpage>
<history>
<date date-type="received">
<day>09</day>
<month>6</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>14</day>
<month>3</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>3</month>
<year>2019</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2019 International League Against Epilepsy <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2019 The Authors. <italic>Epilepsia</italic> published by Wiley Periodicals, Inc. on behalf of International League Against Epilepsy.</copyright-statement>
<license license-type="creativeCommonsBy">
<license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="file:EPI-60-818.pdf" xlink:type="simple"></self-uri>
<abstract id="epi14722-abs-0001">
<title>Summary</title>
<sec id="epi14722-sec-0001">
<title>Objective</title>
<p>The true prevalence of epileptic seizures and epilepsy in 22q11.2 deletion syndrome (22q11.2<styled-content style="fixed-case">DS</styled-content>) is unknown, because previous studies have relied on historical medical record review. Associations of epilepsy with other neurodevelopmental manifestations (eg, specific psychiatric diagnoses) remain unexplored.</p>
</sec>
<sec id="epi14722-sec-0002">
<title>Methods</title>
<p>The primary caregivers of 108 deletion carriers (mean age 13.6 years) and 60 control siblings (mean age 13.1 years) completed a validated epilepsy screening questionnaire. A subsample (n = 44) underwent a second assessment with interview, prolonged electroencephalography (<styled-content style="fixed-case">EEG),</styled-content> and medical record and epileptologist review. <styled-content style="fixed-case">Intelligence quotient (IQ)</styled-content>, psychopathology, and other neurodevelopmental problems were examined using neurocognitive assessment and questionnaire/interview.</p>
</sec>
<sec id="epi14722-sec-0003">
<title>Results</title>
<p>Eleven percent (12/108) of deletion carriers had an epilepsy diagnosis (controls 0%, <italic>P</italic> = 0.004). Fifty‐seven of the remaining 96 deletion carriers (59.4%) had seizures or seizurelike symptoms (controls 13.3%, 8/60, <italic>P</italic> &lt; 0.001). A febrile seizure was reported for 24.1% (26/107) of cases (controls 0%, <italic>P</italic> &lt; 0.001). One deletion carrier with a clinical history of epilepsy was diagnosed with an additional type of unprovoked seizure during the second assessment. One deletion carrier was newly diagnosed with epilepsy, and two more with possible nonmotor absence seizures. A positive screen on the epilepsy questionnaire was more likely in deletion carriers with lower performance <styled-content style="fixed-case">IQ</styled-content> (odds ratio [<styled-content style="fixed-case">OR]</styled-content> 0.96, <italic>P</italic> = 0.018), <styled-content style="fixed-case">attention‐deficit/hyperactivity disorder (ADHD</styled-content>) (<styled-content style="fixed-case">OR</styled-content> 3.28, <italic>P</italic> = 0.021), autism symptoms (<styled-content style="fixed-case">OR</styled-content> 3.86, <italic>P</italic> = 0.004), and indicative motor coordination disorder (<styled-content style="fixed-case">OR</styled-content> 4.56, <italic>P</italic> = 0.021).</p>
</sec>
<sec id="epi14722-sec-0004">
<title>Significance</title>
<p>Even when accounting for deletion carriers diagnosed with epilepsy, reports of seizures and seizurelike symptoms are common. These may be “true” epileptic seizures in some cases, which are not recognized during routine clinical care. Febrile seizures were far more common in deletion carriers compared to known population risk. A propensity for seizures in 22q11.2<styled-content style="fixed-case">DS</styled-content> was associated with cognitive impairment, psychopathology, and motor coordination problems. Future research is required to determine whether this reflects common neurobiologic risk pathways or is a consequence of recurrent seizures.</p>
</sec>
</abstract>
<kwd-group kwd-group-type="author-generated">
<kwd id="epi14722-kwd-0001">electroencephalography</kwd>
<kwd id="epi14722-kwd-0002">febrile seizure</kwd>
<kwd id="epi14722-kwd-0003">psychiatric disorder</kwd>
<kwd id="epi14722-kwd-0004">seizure semiology</kwd>
<kwd id="epi14722-kwd-0005">unprovoked seizure</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>Medical Research Council Doctoral Training</funding-source>
<award-id>1644194</award-id>
</award-group>
<award-group>
<funding-source>Medical Research Council Centre</funding-source>
<award-id>G0801418</award-id>
</award-group>
<award-group>
<funding-source>Medical Research Council Programme</funding-source>
<award-id>G0800509</award-id>
</award-group>
<award-group>
<funding-source>National Institute of Mental Health</funding-source>
<award-id>NIMH 5UO1MH101724</award-id>
</award-group>
<award-group>
<funding-source>Wellcome Trust</funding-source>
<award-id>503147</award-id>
</award-group>
<award-group>
<funding-source>Wellcome Trust Institutional Strategic Support Fund (ISSF)</funding-source>
</award-group>
<award-group>
<funding-source>Waterloo Foundation</funding-source>
<award-id>WF918‐1234</award-id>
</award-group>
<award-group>
<funding-source>Baily Thomas Charitable Fund</funding-source>
<award-id>2315/1</award-id>
</award-group>
<award-group>
<funding-source>Health &amp; Care Research Wales</funding-source>
<award-id>507556</award-id>
</award-group>
</funding-group>
<counts>
<fig-count count="1"></fig-count>
<table-count count="5"></table-count>
<page-count count="12"></page-count>
<word-count count="8284"></word-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>epi14722</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>May 2019</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.2.1 mode:remove_FC converted:15.05.2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<p content-type="self-citation">
<mixed-citation id="epi14722-cit-1001" publication-type="journal">
<string-name>
<surname>Eaton</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Hamandi</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Epilepsy and seizures in young people with 22q11.2 deletion syndrome: Prevalence and links with other neurodevelopmental disorders</article-title>. <source xml:lang="en"/>Epilepsia. <year>2019</year>;<volume>60</volume>:<fpage>818</fpage>–<lpage>829</lpage>. <pub-id pub-id-type="doi">10.1111/epi.14722</pub-id>
<pub-id pub-id-type="pmid">30977115</pub-id></mixed-citation>
</p>
<fn-group id="epi14722-ntgp-0001">
<fn id="epi14722-note-1001">
<p>Rhys H. Thomas and Khalid Hamandi contributed equally to this work.</p>
</fn>
<fn fn-type="funding" id="epi14722-note-1002">
<p>
<bold>Funding information</bold>
</p>
<p>This research was funded by a Medical Research Council Doctoral Training Grant (C.B.E. 1644194), Medical Research Council Centre Grant (G0801418) and Medical Research Council Programme Grant (G0800509), the National Institute of Mental Health (NIMH 5UO1MH101724), Wellcome Trust Strategic Award (503147), Wellcome Trust Institutional Strategic Support Fund (ISSF), the Waterloo Foundation (WF 918‐1234), the Baily Thomas Charitable Fund (2315/1), and Health &amp; Care Research Wales (Welsh Government, 507556).</p>
</fn>
</fn-group>
</notes>
</front>
<body>
<p>
<boxed-text content-type="box" id="epi14722-blkfxd-0001" orientation="portrait" position="anchor"><caption><title>Key points</title></caption><p>
<list id="epi14722-list-0001" list-type="bullet"><list-item><p>Over half of young people with 22q11.2 deletion syndrome (22q11.2DS) without an epilepsy diagnosis were reported as having a seizure or seizure‐like symptom</p></list-item><list-item><p>We conducted a second assessment stage in a subsample of 44 people including an interview, a prolonged electroencephalography (EEG) assessment, and a medical record review</p></list-item><list-item><p>This highlighted that in some deletion carriers, epileptic seizures may not be recognized during routine clinical care and that epilepsy may be overlooked</p></list-item><list-item><p>A quarter of young people with 22q11.2DS screened positive for febrile seizures, a higher rate than reported in previous studies in this population</p></list-item><list-item><p>Epilepsy, seizures, and seizurelike symptoms were associated with attention‐deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD) symptoms, motor coordination problems, and a lower performance intelligence quotient (IQ) in 22q11.2DS</p></list-item></list>
</p></boxed-text>
</p>
<sec id="epi14722-sec-0006">
<label>1</label>
<title>INTRODUCTION</title>
<p>The most common recurrent microdeletion syndrome in humans is 22q11.2 deletion syndrome (22q11.2DS), which occurs in ~1 in 2000‐4000 live births.<xref ref-type="ref" rid="epi14722-bib-0001">1</xref> In the majority of cases, a de novo 3 megabase (Mb) deletion occurs between low copy repeats (LCRs) 22A‐22D, causing the loss of 46 protein‐coding genes.<xref ref-type="ref" rid="epi14722-bib-0002">2</xref> This deletion syndrome has a variable phenotype, with characteristic features including congenital heart disease, palatal abnormalities, hypocalcemia, mild‐moderate intellectual disability (ID), and psychiatric disorders such as schizophrenia, attention‐deficit/hyperactivity disorder (ADHD), anxiety disorder and autism spectrum disorder (ASD).<xref ref-type="ref" rid="epi14722-bib-0003">3</xref>, <xref ref-type="ref" rid="epi14722-bib-0004">4</xref>, <xref ref-type="ref" rid="epi14722-bib-0005">5</xref>, <xref ref-type="ref" rid="epi14722-bib-0006">6</xref>, <xref ref-type="ref" rid="epi14722-bib-0007">7</xref>, <xref ref-type="ref" rid="epi14722-bib-0008">8</xref>, <xref ref-type="ref" rid="epi14722-bib-0009">9</xref>, <xref ref-type="ref" rid="epi14722-bib-0010">10</xref>, <xref ref-type="ref" rid="epi14722-bib-0011">11</xref>
</p>
<p>The deletion increases the risk of acute symptomatic and unprovoked epileptic seizures, although the reported rates are wide‐ranging. Between 1% and 14.5% of patients have hypocalcemia‐induced seizures.<xref ref-type="ref" rid="epi14722-bib-0012">12</xref>, <xref ref-type="ref" rid="epi14722-bib-0013">13</xref>, <xref ref-type="ref" rid="epi14722-bib-0014">14</xref>, <xref ref-type="ref" rid="epi14722-bib-0015">15</xref>, <xref ref-type="ref" rid="epi14722-bib-0016">16</xref> In adulthood, 17.6% of patients with 22q11.2DS exposed to psychotropic drugs have epileptic seizures, suggesting a reduced seizure threshold.<xref ref-type="ref" rid="epi14722-bib-0013">13</xref> Between 4.4% and 36.8% have repeated unprovoked seizures (ie, epilepsy).<xref ref-type="ref" rid="epi14722-bib-0009">9</xref>, <xref ref-type="ref" rid="epi14722-bib-0013">13</xref>, <xref ref-type="ref" rid="epi14722-bib-0014">14</xref>, <xref ref-type="ref" rid="epi14722-bib-0015">15</xref>, <xref ref-type="ref" rid="epi14722-bib-0017">17</xref>, <xref ref-type="ref" rid="epi14722-bib-0018">18</xref> Structural brain abnormalities in these individuals can include diffuse cerebral atrophy (18.8%), polymicrogyria (13.9%), hippocampal malrotation (10.9%), gray and white matter heterotopia (5.9%), and focal cortical dysplasia (2%).<xref ref-type="ref" rid="epi14722-bib-0019">19</xref> Between 1% and 6.9% of patients have genetic generalized epilepsy (GGE),<xref ref-type="ref" rid="epi14722-bib-0013">13</xref>, <xref ref-type="ref" rid="epi14722-bib-0014">14</xref>, <xref ref-type="ref" rid="epi14722-bib-0015">15</xref>, <xref ref-type="ref" rid="epi14722-bib-0017">17</xref> and the deletion prevalence is elevated in GGE cohorts.<xref ref-type="ref" rid="epi14722-bib-0020">20</xref>
</p>
<p>To date, studies investigating the prevalence of epileptic seizures and epilepsy in deletion carriers have relied on retrospective medical record review. Such records are less suited to systematic evaluation, because of differences between clinicians in diagnostic methods and documentation. This approach may furthermore miss cases of nonconvulsive seizures (eg, absences) not seen clinically. Nonconvulsive seizures normally occur several times before the affected individual and their family seek clinical advice.<xref ref-type="ref" rid="epi14722-bib-0021">21</xref> Andrade et al (2013) were the first to conduct a direct, systematic study of epilepsy in 22q11.2DS, including epileptologist, magnetic resonance imaging (MRI), and prolonged electroencephalography (EEG) assessment. They observed that 36.8% of patients had epilepsy, although their sample consisted of 19 adults only.<xref ref-type="ref" rid="epi14722-bib-0018">18</xref> Thus, previous research may have underestimated the prevalence of epileptic seizures and epilepsy in 22q11.2DS, particularly in young people. In addition, there is a dearth of research into salient seizure characteristics in 22q11.2DS, such as length and frequency, increases in which associate with poorer neurodevelopmental outcomes in the general population.<xref ref-type="ref" rid="epi14722-bib-0022">22</xref>, <xref ref-type="ref" rid="epi14722-bib-0023">23</xref>
</p>
<p>Studies based primarily on historical medical record review have also assessed the relationships of epileptic seizures and epilepsy with cognitive and psychiatric development in 22q11.2DS. Neonatal seizures (mostly hypocalcemia‐induced) predict poorer intellectual functioning later in life.<xref ref-type="ref" rid="epi14722-bib-0016">16</xref> Epilepsy also associates with a higher rate of developmental delay, but not with psychiatric disorder.<xref ref-type="ref" rid="epi14722-bib-0017">17</xref> The relationships of epilepsy with specific psychiatric diagnoses (eg, ADHD) and other salient manifestations of 22q11.2DS, such as sleep disturbance<xref ref-type="ref" rid="epi14722-bib-0024">24</xref> and motor coordination problems,<xref ref-type="ref" rid="epi14722-bib-0004">4</xref> have not been explored.</p>
<p>Our study had three aims: First, we explored the rates of an epilepsy diagnosis, seizures, and seizurelike symptoms (behaviors that may reflect unrecognized epileptic seizures) in young people with 22q11.2DS and their unaffected control siblings, through data obtained from a validated questionnaire completed by the primary caregiver. To support these findings, we conducted a second stage of assessment with a subsample, involving primary caregiver interview, prolonged EEG assessment, and a medical record review. These data were then reviewed by an epileptologist, who made diagnoses of epileptic seizures and epilepsy.</p>
<p>Second, we sought to delineate salient seizure characteristics in deletion carriers who took part in the second assessment, such as etiology, semiology, age at onset, length, and frequency.</p>
<p>Third, we investigated whether epilepsy questionnaire responses were predicted by intellectual functioning (IQ and ID), psychopathology (ADHD, anxiety disorder, and indicative ASD), motor coordination problems, and sleep disturbance in deletion carriers.</p>
</sec>
<sec id="epi14722-sec-0007">
<label>2</label>
<title>METHODS</title>
<sec id="epi14722-sec-0008">
<label>2.1</label>
<title>Participants</title>
<p>We recruited 108 deletion carriers (57.4% male, mean age 13.6 years, standard deviation [SD] 3.3, range 6.2‐20.5) and 60 unaffected control siblings (50% male, mean age 13.1 years, SD 3.2, range 6.3‐18.9) via UK genetics clinics and charities for chromosomal conditions. The deletion was identified in the clinics (fluorescence in situ hybridization/microarray) and confirmed in the MRC Centre for Neuropsychiatric Genetics and Genomics laboratory (microarray). For 15.8% of cases, information about deletion size was not provided and we could not obtain a biologic sample for verification. In the remainder, the majority had the typical de novo ~3 megabase (Mb) A‐D deletion and all were haploinsufficient for <italic>TBX1</italic>, except for one atypical B‐D deletion (Table <xref ref-type="table" rid="epi14722-tbl-0001">1</xref>). We obtained informed written consent from primary caregivers and participants. The National Health Service Wales Research Ethics Committee approved our protocols.</p>
<table-wrap id="epi14722-tbl-0001" orientation="portrait" position="float" xml:lang="en">
<label>Table 1</label>
<caption>
<p>Descriptive statistics of the sample</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top"></th>
<th align="left" colspan="1" rowspan="1" valign="top">%</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="2" rowspan="1">Deletion etiology</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">De novo</td>
<td align="char" char="." colspan="1" rowspan="1">77.8</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Inherited</td>
<td align="char" char="." colspan="1" rowspan="1">8.3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Unknown</td>
<td align="char" char="." colspan="1" rowspan="1">13.9</td>
</tr>
<tr>
<td align="left" colspan="2" rowspan="1">Deletion type</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">~3 Mb A‐D</td>
<td align="char" char="." colspan="1" rowspan="1">75.9</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">~2 Mb A‐C</td>
<td align="char" char="." colspan="1" rowspan="1">0.9</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">~1.5 Mb A‐B</td>
<td align="char" char="." colspan="1" rowspan="1">6.5</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Atypical ~1.5 Mb B‐D</td>
<td align="char" char="." colspan="1" rowspan="1">0.9</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Unknown</td>
<td align="char" char="." colspan="1" rowspan="1">15.8</td>
</tr>
<tr>
<td align="left" colspan="2" rowspan="1">Family ethnic background</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">European</td>
<td align="char" char="." colspan="1" rowspan="1">85.2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Mixed</td>
<td align="char" char="." colspan="1" rowspan="1">10.2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Non‐European</td>
<td align="char" char="." colspan="1" rowspan="1">1.9</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Unknown</td>
<td align="char" char="." colspan="1" rowspan="1">2.8</td>
</tr>
<tr>
<td align="left" colspan="2" rowspan="1">Highest parental qualification<xref ref-type="fn" rid="epi14722-note-0003">a</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Low (O‐levels/GCSEs)</td>
<td align="char" char="." colspan="1" rowspan="1">23.2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Middle (A‐levels/highers/vocational training)</td>
<td align="char" char="." colspan="1" rowspan="1">32.4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">High (university degree and/or other higher postgraduate qualification)</td>
<td align="char" char="." colspan="1" rowspan="1">32.4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Unknown</td>
<td align="char" char="." colspan="1" rowspan="1">12.0</td>
</tr>
<tr>
<td align="left" colspan="2" rowspan="1">Family income</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">≤£19 999</td>
<td align="char" char="." colspan="1" rowspan="1">22.2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">£20 000‐£39 999</td>
<td align="char" char="." colspan="1" rowspan="1">24.1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">£40 000‐£59 999</td>
<td align="char" char="." colspan="1" rowspan="1">21.3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">≥£60 000</td>
<td align="char" char="." colspan="1" rowspan="1">23.1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Unknown</td>
<td align="char" char="." colspan="1" rowspan="1">9.3</td>
</tr>
</tbody>
</table>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top"></th>
<th align="left" colspan="1" rowspan="1" valign="top">Mean</th>
<th align="left" colspan="1" rowspan="1" valign="top">SD</th>
<th align="left" colspan="1" rowspan="1" valign="top">Range</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="4" rowspan="1">Age</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">22q11.2DS</td>
<td align="char" char="." colspan="1" rowspan="1">13.6</td>
<td align="char" char="." colspan="1" rowspan="1">3.3</td>
<td align="char" char="." colspan="1" rowspan="1">6.2‐20.5</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Controls</td>
<td align="char" char="." colspan="1" rowspan="1">13.1</td>
<td align="char" char="." colspan="1" rowspan="1">3.2</td>
<td align="char" char="." colspan="1" rowspan="1">6.3‐18.9</td>
</tr>
</tbody>
</table>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top"></th>
<th align="left" colspan="1" rowspan="1" valign="top">Male (%)</th>
<th align="left" colspan="1" rowspan="1" valign="top">Female (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="3" rowspan="1">Gender</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">22q11.2DS</td>
<td align="char" char="." colspan="1" rowspan="1">62 (57.4)</td>
<td align="char" char="." colspan="1" rowspan="1">46 (42.6)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Controls</td>
<td align="char" char="." colspan="1" rowspan="1">30 (50)</td>
<td align="char" char="." colspan="1" rowspan="1">30 (50)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="epi14722-note-0002">
<p>GCSE, General Certificate of Secondary Education; 22q11.2DS, 22q11.2 deletion syndrome.</p>
</fn>
<fn id="epi14722-note-0003">
<label>a</label>
<p>Of the parent completing the questionnaire.</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
</sec>
<sec id="epi14722-sec-0009">
<label>2.2</label>
<title>Screening for lifetime history of epilepsy, seizures, and seizurelike symptoms</title>
<p>We used the validated Epilepsy Screening Questionnaire (ESQ; Ottman et al,<xref ref-type="ref" rid="epi14722-bib-0025">25</xref> Table <xref ref-type="table" rid="epi14722-tbl-0002">2</xref>) to screen for an epilepsy diagnosis (Item 9), seizures (Items 1 and 2) and seizurelike symptoms (behaviors that may reflect unrecognized epileptic seizures, Items 3‐8). We created two dichotomous summary variables: “any positive,” a positive response (“yes” or “possibly”) to at least one item; and “any positive excluding epilepsy,” a positive response to any of Item 1 to Item 8 in those without epilepsy. The ESQ was originally self‐report<xref ref-type="ref" rid="epi14722-bib-0025">25</xref>; however, we asked the primary caregiver to complete it in all cases, given the age and presence of mild‐moderate ID in our 22q11.2DS sample.<xref ref-type="ref" rid="epi14722-bib-0003">3</xref> In the Ottman et al<xref ref-type="ref" rid="epi14722-bib-0025">25</xref> validation study, participants were only asked about afebrile seizures and seizurelike symptoms if they didn't have epilepsy. We asked all items, to probe for unrecognized seizures in epilepsy patients.</p>
<table-wrap id="epi14722-tbl-0002" orientation="portrait" position="float" xml:lang="en">
<label>Table 2</label>
<caption>
<p>Rates of positive responses on each item of the Epilepsy Screening Questionnaire in young people with 22q11.2DS and their unaffected control siblings</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="2" valign="top">Item</th>
<th align="left" colspan="2" rowspan="1" style="border-bottom:solid 1px #000000" valign="top">Positive response</th>
<th align="left" colspan="1" rowspan="2" valign="top">χ<sup>2</sup>
</th>
<th align="left" colspan="1" rowspan="2" valign="top">OR</th>
<th align="left" colspan="1" rowspan="2" valign="top">
<italic>P</italic> value</th>
</tr>
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">22q11.2DS, n (%)</th>
<th align="left" colspan="1" rowspan="1" valign="top">Controls, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">1. Did your son/daughter ever have a seizure or convulsion caused by a high fever?<xref ref-type="fn" rid="epi14722-note-0005">a</xref>
</td>
<td align="char" char=" " colspan="1" rowspan="1">26 (24.3)</td>
<td align="char" char=" " colspan="1" rowspan="1">0 (0)</td>
<td align="left" colspan="1" rowspan="1">17</td>
<td align="char" char="." colspan="1" rowspan="1">_</td>
<td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">2. Other than the seizures associated with high fevers, has your son/daughter ever had a seizure, convulsion, fit, or spell—under any circumstances?<xref ref-type="fn" rid="epi14722-note-0006">b</xref>
</td>
<td align="char" char=" " colspan="1" rowspan="1">26 (24.1)</td>
<td align="char" char=" " colspan="1" rowspan="1">0 (0)</td>
<td align="left" colspan="1" rowspan="1">16.8</td>
<td align="char" char="." colspan="1" rowspan="1">_</td>
<td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">3. Other than the seizures associated with high fevers, has your son/daughter ever had uncontrolled movements of part or all of his/her body such as twitching, jerking, shaking, or going limp?<xref ref-type="fn" rid="epi14722-note-0007">c</xref>
</td>
<td align="char" char=" " colspan="1" rowspan="1">21 (19.8)</td>
<td align="char" char=" " colspan="1" rowspan="1">2 (3.3)</td>
<td align="left" colspan="1" rowspan="1">8.72</td>
<td align="char" char="." colspan="1" rowspan="1">7.1</td>
<td align="char" char="." colspan="1" rowspan="1">0.003</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">4. Other than the seizures associated with high fevers, has your son/daughter ever had an unexplained change in his/her mental state or level of awareness; or an episode of “spacing out” that he/she could not control?<xref ref-type="fn" rid="epi14722-note-0008">d</xref>
</td>
<td align="char" char=" " colspan="1" rowspan="1">19 (17.8)</td>
<td align="char" char=" " colspan="1" rowspan="1">1 (1.7)</td>
<td align="left" colspan="1" rowspan="1">9.44</td>
<td align="char" char="." colspan="1" rowspan="1">12.6</td>
<td align="char" char="." colspan="1" rowspan="1">0.002</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">5. Does your son/daughter daydream or stare into space more than other children?</td>
<td align="char" char=" " colspan="1" rowspan="1">43 (40.2)</td>
<td align="char" char=" " colspan="1" rowspan="1">5 (8.3)</td>
<td align="left" colspan="1" rowspan="1">19</td>
<td align="char" char="." colspan="1" rowspan="1">7.31</td>
<td align="char" char="." colspan="1" rowspan="1">&lt;0.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">6. Have you ever noticed him/her to have any unusual body movements when exposed to strobe lights, video games, flickering lights, or sun glare?</td>
<td align="char" char=" " colspan="1" rowspan="1">3 (2.8)</td>
<td align="char" char=" " colspan="1" rowspan="1">0 (0)</td>
<td align="left" colspan="1" rowspan="1">Fisher's exact test</td>
<td align="char" char="." colspan="1" rowspan="1">_</td>
<td align="char" char="." colspan="1" rowspan="1">0.553</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">7. Shortly after waking up, either in the morning or after a nap, have you ever noticed your son/daughter have uncontrollable jerking or clumsiness, such as dropping things or things suddenly flying from his/her hands?</td>
<td align="char" char=" " colspan="1" rowspan="1">10 (9.3)</td>
<td align="char" char=" " colspan="1" rowspan="1">0 (0)</td>
<td align="left" colspan="1" rowspan="1">Fisher's exact test</td>
<td align="char" char="." colspan="1" rowspan="1">_</td>
<td align="char" char="." colspan="1" rowspan="1">0.014</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">8. Has your son/daughter ever had any other type of repeated unusual spells?</td>
<td align="char" char=" " colspan="1" rowspan="1">7 (6.5)</td>
<td align="char" char=" " colspan="1" rowspan="1">0 (0)</td>
<td align="left" colspan="1" rowspan="1">Fisher's exact test</td>
<td align="char" char="." colspan="1" rowspan="1">_</td>
<td align="char" char="." colspan="1" rowspan="1">0.051</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">9. Has your son/daughter ever been diagnosed with a seizure disorder or epilepsy?</td>
<td align="char" char=" " colspan="1" rowspan="1">12 (11.1)</td>
<td align="char" char=" " colspan="1" rowspan="1">0 (0)</td>
<td align="left" colspan="1" rowspan="1">Fisher's exact test</td>
<td align="char" char="." colspan="1" rowspan="1">_</td>
<td align="char" char="." colspan="1" rowspan="1">0.004</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="epi14722-note-0004">
<p>22q11.2DS, 22q11.2 deletion syndrome; OR, odds ratio.</p>
</fn>
<fn id="epi14722-note-0005">
<label>a</label>
<p>Data available for 107 probands and 59 control siblings.</p>
</fn>
<fn id="epi14722-note-0006">
<label>b</label>
<p>Data available for 59 control siblings.</p>
</fn>
<fn id="epi14722-note-0007">
<label>c</label>
<p>Data available for 106 probands.</p>
</fn>
<fn id="epi14722-note-0008">
<label>d</label>
<p>Data available for 107 probands.</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
</sec>
<sec id="epi14722-sec-0010">
<label>2.3</label>
<title>Second stage of assessment of epileptic seizures and epilepsy</title>
<p>To validate our screening findings, we conducted a second assessment in a subsample of 40 deletion carriers and 4 controls with “any positive.”</p>
<p>A trained researcher interviewed the primary caregiver about ESQ‐reported events (for 37 deletion carriers and 4 controls), using an amended version of the validated Seizure Classification Interview (SCI), developed by Ottman et al.<xref ref-type="ref" rid="epi14722-bib-0026">26</xref>, <xref ref-type="ref" rid="epi14722-bib-0027">27</xref> Diagnoses from the SCI show fair to excellent nonchance agreement with neurologist diagnoses in studies of epilepsy patients (<italic>k</italic> = 0.54‐0.83).<xref ref-type="ref" rid="epi14722-bib-0026">26</xref> We used the interview to establish whether ESQ‐reported events were epileptic seizures. We therefore combined the “grand mal” and “small seizures” sections into an “unusual spell” section. In addition, we added a section on febrile seizures specifically. We undertook medical record reviews where available (11 deletion carriers).</p>
<p>We conducted prolonged ambulatory EEG with 28 deletion carriers and 4 controls, with overnight video‐monitoring (22q11.2DS: mean recording length 13:41:16, SD 04:59:40, range 3:30:00‐21:03:06, controls: mean 11:14:38, SD 05:14:36, range 03:25:00‐14:25:23). Recordings were performed using a 64‐channel Hydrocel Geodesic Sensor Net (Electrical Geodesics Inc.) and a BE PLUS LTM amplifier (EB Neuro S.p.A.).</p>
<p>A consultant epileptologist and a consultant neurophysiologist reviewed the EEG traces, and participants had their epileptic seizures classified and epilepsy diagnosed by the epileptologist, according to International League Against Epilepsy (ILAE) criteria.<xref ref-type="ref" rid="epi14722-bib-0028">28</xref>, <xref ref-type="ref" rid="epi14722-bib-0029">29</xref>, <xref ref-type="ref" rid="epi14722-bib-0030">30</xref>
</p>
</sec>
<sec id="epi14722-sec-0011">
<label>2.4</label>
<title>IQ and psychopathology</title>
<p>We derived the child's full‐scale IQ (FSIQ), performance IQ (PIQ) and verbal IQ (VIQ) scores from the Wechsler Abbreviated Scale of Intelligence (WASI).<xref ref-type="ref" rid="epi14722-bib-0031">31</xref> ID was defined as FSIQ &lt;70. We conducted the Child and Adolescent Psychiatric Assessment interview (CAPA)<xref ref-type="ref" rid="epi14722-bib-0032">32</xref> with the primary caregiver to diagnose ADHD and anxiety disorder, according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM‐IV‐TR)<xref ref-type="ref" rid="epi14722-bib-0033">33</xref> criteria. We screened for indicative ASD using the Social Communication Questionnaire,<xref ref-type="ref" rid="epi14722-bib-0034">34</xref> completed by the primary caregiver.</p>
</sec>
<sec id="epi14722-sec-0012">
<label>2.5</label>
<title>Other neurodevelopmental problems</title>
<p>We screened for indicative developmental coordination disorder (DCD) using the Developmental Coordination Disorder Questionnaire (DCDQ),<xref ref-type="ref" rid="epi14722-bib-0035">35</xref>, <xref ref-type="ref" rid="epi14722-bib-0036">36</xref> completed by the primary caregiver. Sleep disturbance was defined as a score of two on one item from the CAPA sleep section. Primary caregivers provided information on preterm birth, cardiovascular problems, recurrent infections, and lifetime medication use.</p>
<p>Sample sizes for the ESQ, IQ, psychopathology, and other neurodevelopmental problem datasets differed due to the child or parent not completing part/all of one or more measures. The primary caregiver was not available for the SCI for three deletion carriers who underwent EEG.</p>
</sec>
<sec id="epi14722-sec-0013">
<label>2.6</label>
<title>Statistical analyses</title>
<p>Statistical analyses were conducted in R version 3.5.1 (<ext-link ext-link-type="uri" xlink:href="https://www.R-project.org/">https://www.R-project.org/</ext-link>).</p>
<sec id="epi14722-sec-0014">
<label>2.6.1</label>
<title>Screening for lifetime history of epilepsy, seizures, and seizurelike symptoms</title>
<p>We used logistic regression analyses to measure associations between deletion status (22q11.2DS/control) and the “any positive” and “any positive excluding epilepsy” variables. Predictors were entered hierarchically: age first, then gender, then deletion status. We conducted a sensitivity analysis to explore whether preterm birth, cardiovascular problems, and lifetime history of psychotropic and/or antiepileptic medication use influenced our findings. We explored associations between deletion status and response to each ESQ item using χ<sup>2</sup>/Fisher's exact test. We conducted a logistic regression exploring whether recurrent infections predicted febrile seizures in deletion carriers.</p>
</sec>
<sec id="epi14722-sec-0015">
<label>2.6.2</label>
<title>Second stage of assessment of epileptic seizures and epilepsy</title>
<p>For the “epilepsy diagnosis” and “any positive excluding epilepsy” ESQ variables, we calculated the percentage of deletion carriers who were diagnosed with epilepsy and epileptic seizures by our epileptologist, respectively, as well as the rates of epileptiform discharges in these groups; no background abnormalities were observed. We also calculated the percentage of deletion carriers reported with febrile seizures (Item 1, Table <xref ref-type="table" rid="epi14722-tbl-0002">2</xref>) who had their report confirmed by our epileptologist. For controls, we repeated these analyses with the “any positive excluding epilepsy” ESQ variable only (no controls had epileptic seizures or abnormal EEG findings).</p>
<p>We calculated the rate of different seizure etiologies in deletion carriers who were diagnosed with epileptic seizures. We also explored characteristics of febrile and unprovoked seizures (the most common seizure etiologies in our sample) such as the semiology (rates of generalized and focal seizures), median age at onset (months), median number, median length (seconds), and frequency (rates of four different categories; Table <xref ref-type="table" rid="epi14722-tbl-0004">4</xref>; eg, less than once a month).</p>
</sec>
<sec id="epi14722-sec-0016">
<label>2.6.3</label>
<title>Association of the ESQ with neurodevelopmental problems in 22q11.2DS</title>
<p>In deletion carriers, we used logistic regression analyses to explore the associations of the “any positive” “any positive excluding epilepsy” and “febrile seizure” ESQ variables with IQ scores, ID, psychopathology, indicative DCD, and sleep disturbance. Predictors were entered hierarchically, age first, then gender, and finally the neurodevelopmental variable. We compared FSIQ, VIQ, and PIQ scores and rates of ID, psychopathology, indicative DCD, and sleep disturbance between deletion carriers and controls using <italic>t</italic> tests and χ<sup>2</sup> tests.</p>
</sec>
</sec>
</sec>
<sec id="epi14722-sec-0017">
<label>3</label>
<title>RESULTS</title>
<p>Table <xref ref-type="table" rid="epi14722-tbl-0001">1</xref> displays descriptive statistics about our sample.</p>
<sec id="epi14722-sec-0018">
<label>3.1</label>
<title>Screening for lifetime history of epilepsy, seizures, and seizurelike symptoms</title>
<p>Table <xref ref-type="table" rid="epi14722-tbl-0002">2</xref> shows the rates of positive responses on each ESQ item. Sixty‐nine of 108 <bold>(</bold>63.9%) deletion carriers had “any positive” compared to 13.3% (8/60) of controls (<italic>b = </italic>2.49, <italic>z </italic>= 5.67, odds ratio [OR] 12, <italic>P</italic> &lt; 0.001). Of deletion carriers, 11.1% (12/108) had an epilepsy diagnosis, yet when excluding these cases 59.4% (57/96) had “any positive excluding epilepsy” compared to 13.3% (8/60) of controls (<italic>b </italic>=<italic> </italic>2.27, <italic>z</italic> = 5.15, OR 9.66, <italic>P</italic> &lt; 0.001). Around a quarter of deletion carriers had febrile seizures (controls 0%, <italic>P</italic> &lt; 0.001, Table <xref ref-type="table" rid="epi14722-tbl-0002">2</xref>). Positive responses were significantly more common in deletion carriers than in controls for four of the seizurelike symptom items (Items 3, 4, 5, and 7 in Table <xref ref-type="table" rid="epi14722-tbl-0002">2</xref>). Age and gender did not influence these relationships.</p>
<p>Nineteen of 108 (17.6%) deletion carriers had a lifetime history of psychotropic and/or antiepileptic medication use. Fourteen of 103 cases (13.6%) and 4.3% (2/46) of controls were born prematurely; 64.8% (68/105) of cases and 1.8% (1/59) of controls had cardiovascular problems. These comorbidities did not influence our findings.</p>
<p>The majority of deletion carriers had recurrent infections (68.9%, 73/106, controls 10.9%, 6/55; <italic>P</italic> &lt; 0.001). Deletion carriers with recurrent infections were not more likely to report febrile seizures, however (<italic>b </italic>=<italic> </italic>0.78, <italic>z</italic> = 1.41, <italic>P</italic> = 0.157).</p>
</sec>
<sec id="epi14722-sec-0019">
<label>3.2</label>
<title>Second stage of assessment of epileptic seizures and epilepsy</title>
<p>Deletion carriers in the second assessment did not differ significantly from those who did not take part with respect to their FSIQ score, rate of psychopathology, or highest level of parental education (<italic>P</italic> &gt; 0.05 in all cases), although they were significantly older (14.4 years vs 12.17 years, <italic>P</italic> = 0.005). The results from the second assessment are shown in Table <xref ref-type="table" rid="epi14722-tbl-0003">3</xref>. For most deletion carriers reported as having epilepsy, whose caregiver was subsequently interviewed, the diagnosis was confirmed (5/6, 83%). The remaining individual had an isolated unprovoked generalized tonic–clonic seizure (GTCS). One deletion carrier was reported as having epilepsy based on a history of what a pediatrician had described as “petit mal” seizures. We reclassified these as focal nonmotor seizures with impaired awareness, in the context of right‐hemisphere polymicrogyria (reported during the SCI). For this participant, we further diagnosed a report of repeated left‐sided numbness and clumsiness in the morning as focal motor (postictal) seizures, thereby identifying an additional seizure type.</p>
<table-wrap id="epi14722-tbl-0003" orientation="portrait" position="float" xml:lang="en">
<label>Table 3</label>
<caption>
<p>Results from the second stage of assessment in young people with 22q11.2DS and control siblings</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">ESQ variable</th>
<th align="left" colspan="1" rowspan="1" valign="top">n screening positive/total n (%)</th>
<th align="left" colspan="1" rowspan="1" valign="top">Interview completed? (%)</th>
<th align="left" colspan="1" rowspan="1" valign="top">Diagnosis confirmed by epileptologist? (%)</th>
<th align="left" colspan="1" rowspan="1" valign="top">EEG completed? (%)</th>
<th align="left" colspan="1" rowspan="1" valign="top">Epileptiform discharges? (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="6" rowspan="1">22q11.2DS</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">ESQ: epilepsy diagnosis</td>
<td align="char" char=" " colspan="1" rowspan="1">12/108 (11.1)</td>
<td align="char" char="." colspan="1" rowspan="1">6/12 (50)</td>
<td align="char" char="." colspan="1" rowspan="1">5/6 (83.3)</td>
<td align="char" char=" " colspan="1" rowspan="1">2/12 (16.7)</td>
<td align="char" char="." colspan="1" rowspan="1">0/2 (0)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">ESQ: “any positive excluding epilepsy”</td>
<td align="char" char=" " colspan="1" rowspan="1">57/96 (59.4)</td>
<td align="char" char="." colspan="1" rowspan="1">31/57 (54.4)</td>
<td align="char" char="." colspan="1" rowspan="1">16/31 (51.6)</td>
<td align="char" char=" " colspan="1" rowspan="1">26/57 (45.6)</td>
<td align="char" char="." colspan="1" rowspan="1">3/26 (11.5)</td>
</tr>
<tr>
<td align="left" colspan="6" rowspan="1">Controls</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">ESQ: “any positive excluding epilepsy”</td>
<td align="char" char=" " colspan="1" rowspan="1">8/60 (13.3)</td>
<td align="char" char="." colspan="1" rowspan="1">4/8 (50)</td>
<td align="char" char="." colspan="1" rowspan="1">0/4 (0)</td>
<td align="char" char=" " colspan="1" rowspan="1">4/8 (50)</td>
<td align="char" char="." colspan="1" rowspan="1">0/4 (0)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="epi14722-note-0009">
<p>22q11.2 DS, 22q11.2 deletion syndrome; EEG, electroencephalography; ESQ, Epilepsy Screening Questionnaire.</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<p>Just over half of deletion carriers with “any positive excluding epilepsy,” whose caregiver was subsequently interviewed, were diagnosed with epileptic seizures (16/31; 51.6%). In two, the diagnosis was “possible” nonmotor absence seizures (based on a history of daydreaming spells). Their caregivers reported that they had not seen a clinician for these events. Of interest, the EEG for one of these two displayed short bursts of generalized and left hemisphere spike‐and‐slow‐wave discharges, occurring during sleep and shortly after awakening (Figure <xref ref-type="supplementary-material" rid="epi14722-sup-0001">S1</xref>). A further 2 of the 16 individuals also met criteria for epilepsy. The primary caregiver for one described a history of repeated unprovoked GTCS in the SCI, but no epilepsy diagnosis. However, a child development clinic letter listed epilepsy as a diagnosis. For the other individual, we diagnosed a history of repeated “staring spells” as nonmotor absence seizures. Medical records were unavailable, but the primary caregiver reported that a pediatrician had previously described these as “possible absence seizures” and that further assessments had not been conducted as these events had stopped. Of interest, this child showed brief generalized spike‐and‐slow‐wave epileptiform discharges shortly after awakening. The remaining deletion carriers (15/31) were diagnosed with nonepileptic events (eg, daydreaming), although one showed brief generalized, left and right hemisphere spike‐and‐slow‐wave discharges during sleep. Eighty percent of these individuals (12/15) were only reported to have seizurelike symptoms on the ESQ.</p>
<p>Most deletion carriers with ESQ‐reported febrile seizures, whose caregiver was subsequently interviewed, were diagnosed with febrile seizures (16/17, 94%). The remaining individual had fever‐related delirium. All controls reported as having “any positive excluding epilepsy” were diagnosed with nonepileptic events.</p>
<p>Table <xref ref-type="table" rid="epi14722-tbl-0004">4</xref> shows salient characteristics of epileptic seizures in deletion carriers. Febrile and unprovoked epileptic seizures were the most common seizure etiologies (77.3% and 45.5%, respectively). All febrile seizures were convulsive, with a median estimated length of 2.5 minutes. On average, febrile seizures began within the first 2 years of life and were recurrent. Unprovoked seizures were not linked to a structural etiology in 60% of deletion carriers. In the remaining 40%, unprovoked seizures were seen in children with structural brain abnormalities or potential acquired causes; right hemisphere polymicrogyria, perinatal subdural hematoma, possible postpneumococcal meningitis (SCI‐report only), and neonatal hypoxic‐ischemic encephalopathy (SCI‐report and medical records). Unprovoked seizures were mostly generalized, lasted for ~2 minutes on average, and onset within the first 3 years of life. Thirty percent experienced daily unprovoked seizures at their most frequent. These three individuals had focal motor seizures with postictal left‐sided numbness upon awakening; “possible” nonmotor absence seizures; and GTCS with nonmotor absence seizures.</p>
<table-wrap id="epi14722-tbl-0004" orientation="portrait" position="float" xml:lang="en">
<label>Table 4</label>
<caption>
<p>Rates and characteristics of febrile and unprovoked seizures in young people with 22q11.2DS who took part in the second stage of assessment</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="2" valign="top">Seizure etiology</th>
<th align="left" colspan="1" rowspan="2" valign="top">n/n with epileptic seizures (%)</th>
<th align="left" colspan="2" rowspan="1" valign="top">Seizure semiology (%)</th>
<th align="left" colspan="1" rowspan="2" valign="top">Median age of onset in months (range)<xref ref-type="fn" rid="epi14722-note-0101">a</xref>
</th>
<th align="left" colspan="1" rowspan="2" valign="top">Median seizure length in seconds (range)<xref ref-type="fn" rid="epi14722-note-0102">b</xref>
</th>
<th align="left" colspan="1" rowspan="2" valign="top">Median number of seizures (range)</th>
<th align="left" colspan="4" rowspan="1" style="border-bottom:solid 1px #000000" valign="top">Frequency (%)<xref ref-type="fn" rid="epi14722-note-0103">c</xref>
</th>
</tr>
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">Generalised</th>
<th align="left" colspan="1" rowspan="1" valign="top">Focal</th>
<th align="left" colspan="1" rowspan="1" valign="top">Less than once a month</th>
<th align="left" colspan="1" rowspan="1" valign="top">One to four times a month</th>
<th align="left" colspan="1" rowspan="1" valign="top">More than four times a month but less than once a day</th>
<th align="left" colspan="1" rowspan="1" valign="top">Daily or more</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Febrile</td>
<td align="char" char=" " colspan="1" rowspan="1">17/22 (77.3)</td>
<td align="char" char=" " colspan="1" rowspan="1">17 (100)</td>
<td align="char" char=" " colspan="1" rowspan="1">0 (0)</td>
<td align="char" char=" " colspan="1" rowspan="1">14 (0‐168)</td>
<td align="char" char=" " colspan="1" rowspan="1">150 (10‐900)</td>
<td align="char" char=" " colspan="1" rowspan="1">2 (1‐7)</td>
<td align="char" char=" " colspan="1" rowspan="1">–</td>
<td align="char" char=" " colspan="1" rowspan="1">–</td>
<td align="char" char=" " colspan="1" rowspan="1">–</td>
<td align="char" char=" " colspan="1" rowspan="1">–</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Unprovoked</td>
<td align="char" char=" " colspan="1" rowspan="1">10/22 (45.5)</td>
<td align="char" char=" " colspan="1" rowspan="1">8 (80)</td>
<td align="char" char=" " colspan="1" rowspan="1">2 (20)</td>
<td align="char" char=" " colspan="1" rowspan="1">33.0 (0‐108)</td>
<td align="char" char=" " colspan="1" rowspan="1">135 (3‐330)</td>
<td align="char" char=" " colspan="1" rowspan="1">–</td>
<td align="char" char=" " colspan="1" rowspan="1">3 (30)</td>
<td align="char" char=" " colspan="1" rowspan="1">3 (30)</td>
<td align="char" char=" " colspan="1" rowspan="1">1 (10)</td>
<td align="char" char=" " colspan="1" rowspan="1">3 (30)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Genetic</td>
<td align="char" char=" " colspan="1" rowspan="1">6/22 (27.3)</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="padding-left:10%">Structural</td>
<td align="char" char=" " colspan="1" rowspan="1">4/22 (18.2)</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="epi14722-note-0101">
<label>a</label>
<p>The earliest age when seizures appeared was used for deletion carriers with multiple types of unprovoked seizure. Within the range, “0” refers to deletion carriers who had their first seizure during the first month of life.</p>
</fn>
<fn id="epi14722-note-0102">
<label>b</label>
<p>The time of the longest seizure was used for deletion carriers with seizures of differing lengths.</p>
</fn>
<fn id="epi14722-note-0103">
<label>c</label>
<p>Primary caregivers were asked to indicate the maximum frequency of seizures for their child.</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<p>Other seizure etiologies not shown in Table <xref ref-type="table" rid="epi14722-tbl-0004">4</xref> include hypocalcemia (9.1%, 2/22, GTCS in both cases), cardiac surgery (4.5%, 1/22, focal motor seizure), and hypoxic‐ischemic encephalopathy (4.5%, 1/22, focal motor seizure, possibly to bilateral tonic–clonic).</p>
</sec>
<sec id="epi14722-sec-0020">
<label>3.3</label>
<title>Association of the ESQ with neurodevelopmental problems in 22q11.2DS</title>
<sec id="epi14722-sec-0021">
<label>3.3.1</label>
<title>IQ and ID</title>
<p>The mean FSIQ, PIQ, and VIQ of deletion carriers were significantly lower than in controls (Table <xref ref-type="supplementary-material" rid="epi14722-sup-0002">S1</xref>). One deletion carrier had a higher‐than‐average FSIQ (117), whereas 12.1% (12/99) and 40.4% (40/99) were in the average (86‐115) and borderline ranges (71‐85), respectively; 41.4% (41/99) had mild ID (55‐70) and 5.1% had (5/99) moderate ID (IQ &lt; 55). By contrast, 94.5% (52/55) of control siblings had an average‐or‐higher FSIQ and only 3 (5.5%) had a borderline FSIQ. “Any positive” was more common in deletion carriers with a lower PIQ (<italic>P</italic> = 0.018, Table <xref ref-type="table" rid="epi14722-tbl-0005">5</xref>). This relationship was not observed for “any positive excluding epilepsy” (<italic>P</italic> = 0.060) or febrile seizures (<italic>P</italic> = 0.105). None of the ESQ variables were predicted by FSIQ, VIQ, or ID. Age and gender did not influence our findings.</p>
<table-wrap id="epi14722-tbl-0005" orientation="portrait" position="float" xml:lang="en">
<label>Table 5</label>
<caption>
<p>IQ scores and rates of neurodevelopmental problems for young people with 22q11.2DS on the “any positive” summary variable</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="2" valign="top">Measure</th>
<th align="left" colspan="1" rowspan="2" valign="top">n</th>
<th align="left" colspan="2" rowspan="1" style="border-bottom:solid 1px #000000" valign="top">Any positive</th>
<th align="left" colspan="1" rowspan="2" valign="top">
<italic>b</italic>
</th>
<th align="left" colspan="1" rowspan="2" valign="top">z</th>
<th align="left" colspan="1" rowspan="2" valign="top">OR</th>
<th align="left" colspan="1" rowspan="2" valign="top">
<italic>P</italic> value</th>
</tr>
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">No (SD)</th>
<th align="left" colspan="1" rowspan="1" valign="top">Yes (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">FSIQ</td>
<td align="char" char="." colspan="1" rowspan="1">99</td>
<td align="char" char=" " colspan="1" rowspan="1">73.94 (13.31)</td>
<td align="char" char=" " colspan="1" rowspan="1">70.35 (11.15)</td>
<td align="char" char="." colspan="1" rowspan="1">−0.02</td>
<td align="char" char="." colspan="1" rowspan="1">−1.39</td>
<td align="char" char="." colspan="1" rowspan="1">0.98</td>
<td align="char" char="." colspan="1" rowspan="1">0.163</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PIQ</td>
<td align="char" char="." colspan="1" rowspan="1">99</td>
<td align="char" char=" " colspan="1" rowspan="1">78.49 (14.05)</td>
<td align="char" char=" " colspan="1" rowspan="1">72.31 (10.94)</td>
<td align="char" char="." colspan="1" rowspan="1">−0.04</td>
<td align="char" char="." colspan="1" rowspan="1">−2.36</td>
<td align="char" char="." colspan="1" rowspan="1">0.96</td>
<td align="char" char="." colspan="1" rowspan="1">0.018</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">VIQ</td>
<td align="char" char="." colspan="1" rowspan="1">100</td>
<td align="char" char=" " colspan="1" rowspan="1">73.98 (13.25)</td>
<td align="char" char=" " colspan="1" rowspan="1">72.38 (12.20)</td>
<td align="char" char="." colspan="1" rowspan="1">−0.01</td>
<td align="char" char="." colspan="1" rowspan="1">−0.59</td>
<td align="char" char="." colspan="1" rowspan="1">1</td>
<td align="char" char="." colspan="1" rowspan="1">0.556</td>
</tr>
</tbody>
</table>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="2" valign="top">Neurodevelopmental problem</th>
<th align="left" colspan="1" rowspan="2" valign="top">
n<break></break>
affected/total n
</th>
<th align="left" colspan="2" rowspan="1" style="border-bottom:solid 1px #000000" valign="top">Any positive</th>
<th align="left" colspan="1" rowspan="2" valign="top">
<italic>b</italic>
</th>
<th align="left" colspan="1" rowspan="2" valign="top">z</th>
<th align="left" colspan="1" rowspan="2" valign="top">OR</th>
<th align="left" colspan="1" rowspan="2" valign="top">
<italic>P</italic> value</th>
</tr>
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">No (%)</th>
<th align="left" colspan="1" rowspan="1" valign="top">Yes (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">ID</td>
<td align="char" char="." colspan="1" rowspan="1">42/99</td>
<td align="char" char=" " colspan="1" rowspan="1">17 (36.2)</td>
<td align="char" char=" " colspan="1" rowspan="1">25 (48.1)</td>
<td align="char" char="." colspan="1" rowspan="1">0.44</td>
<td align="char" char="." colspan="1" rowspan="1">1.02</td>
<td align="char" char="." colspan="1" rowspan="1">1.55</td>
<td align="char" char="." colspan="1" rowspan="1">0.921</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Any psychiatric disorder</td>
<td align="char" char="." colspan="1" rowspan="1">53/108</td>
<td align="char" char=" " colspan="1" rowspan="1">33 (56.9)</td>
<td align="char" char=" " colspan="1" rowspan="1">20 (40)</td>
<td align="char" char="." colspan="1" rowspan="1">0.76</td>
<td align="char" char="." colspan="1" rowspan="1">1.87</td>
<td align="char" char="." colspan="1" rowspan="1">2.13</td>
<td align="char" char="." colspan="1" rowspan="1">0.062</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ADHD</td>
<td align="char" char="." colspan="1" rowspan="1">30/106</td>
<td align="char" char=" " colspan="1" rowspan="1">10 (20)</td>
<td align="char" char=" " colspan="1" rowspan="1">20 (35.7)</td>
<td align="char" char="." colspan="1" rowspan="1">1.19</td>
<td align="char" char="." colspan="1" rowspan="1">2.32</td>
<td align="char" char="." colspan="1" rowspan="1">3.28</td>
<td align="char" char="." colspan="1" rowspan="1">0.021</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Any anxiety disorder</td>
<td align="char" char="." colspan="1" rowspan="1">31/108</td>
<td align="char" char=" " colspan="1" rowspan="1">11 (22.0)</td>
<td align="char" char=" " colspan="1" rowspan="1">20 (34.5)</td>
<td align="char" char="." colspan="1" rowspan="1">0.6</td>
<td align="char" char="." colspan="1" rowspan="1">1.36</td>
<td align="char" char="." colspan="1" rowspan="1">1.83</td>
<td align="char" char="." colspan="1" rowspan="1">0.175</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Any sleep problem</td>
<td align="char" char="." colspan="1" rowspan="1">63/107</td>
<td align="char" char=" " colspan="1" rowspan="1">31 (62)</td>
<td align="char" char=" " colspan="1" rowspan="1">32 (56.1)</td>
<td align="char" char="." colspan="1" rowspan="1">−0.24</td>
<td align="char" char="." colspan="1" rowspan="1">−0.59</td>
<td align="char" char="." colspan="1" rowspan="1">0.79</td>
<td align="char" char="." colspan="1" rowspan="1">0.558</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Indicative ASD</td>
<td align="char" char="." colspan="1" rowspan="1">37/90</td>
<td align="char" char=" " colspan="1" rowspan="1">11 (25.6)</td>
<td align="char" char=" " colspan="1" rowspan="1">26 (55.3)</td>
<td align="char" char="." colspan="1" rowspan="1">1.35</td>
<td align="char" char="." colspan="1" rowspan="1">2.86</td>
<td align="char" char="." colspan="1" rowspan="1">3.86</td>
<td align="char" char="." colspan="1" rowspan="1">0.004</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Indicative DCD</td>
<td align="char" char="." colspan="1" rowspan="1">79/95</td>
<td align="char" char=" " colspan="1" rowspan="1">33 (73.3)</td>
<td align="char" char=" " colspan="1" rowspan="1">46 (92.0)</td>
<td align="char" char="." colspan="1" rowspan="1">1.52</td>
<td align="char" char="." colspan="1" rowspan="1">2.31</td>
<td align="char" char="." colspan="1" rowspan="1">4.56</td>
<td align="char" char="." colspan="1" rowspan="1">0.021</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="epi14722-note-0014">
<p>22q11.2DS, 22q11.2 deletion syndrome; SD, standard deviation; ADHD, attention‐deficit/hyperactivity disorder; ASD, autism spectrum disorder; DCD, developmental coordination disorder; FSIQ, full‐scale IQ, ID, intellectual disability; PIQ, performance IQ, VIQ, verbal IQ.</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
</sec>
<sec id="epi14722-sec-0022">
<label>3.3.2</label>
<title>Psychopathology, sleep disturbance, and motor coordination problems</title>
<p>We found higher rates of psychopathology, sleep disturbance, and indicative DCD in cases relative to controls (Table <xref ref-type="supplementary-material" rid="epi14722-sup-0002">S1</xref>). Deletion carriers with ADHD were around three times more likely to have “any positive” and those with indicative ASD and DCD were around four times more likely (Table <xref ref-type="table" rid="epi14722-tbl-0005">5</xref>). The associations with indicative ASD and DCD held for “any positive excluding epilepsy” (<italic>P</italic> = 0.018 and <italic>P</italic> = 0.026, respectively), although the relationship with ADHD disappeared (<italic>P</italic> = 0.163). None of these relationships held for febrile seizures. None of the ESQ variables were predicted by psychiatric disorders as a group, anxiety disorder, or sleep disturbance. Age and gender did not influence our findings.</p>
<p>Overlap between “any positive” indicative DCD, ADHD, and indicative ASD was common in 22q11.2DS (Figure <xref ref-type="fig" rid="epi14722-fig-0001">1</xref>). Of those with indicative DCD, 58.2% (46/79) had “any positive,” as did 70.3% (26/37) with indicative ASD and 66.7% (20/30) with ADHD; 10.6% (10/94) screened positive in all four domains.</p>
<fig fig-type="Figure" id="epi14722-fig-0001" orientation="portrait" position="float" xml:lang="en">
<label>Figure 1</label>
<caption>
<p>Overlap of “any positive” on the Epilepsy Screening Questionnaire, indicative <styled-content style="fixed-case">DCD</styled-content>,<styled-content style="fixed-case"> ADHD</styled-content>, and indicative <styled-content style="fixed-case">ASD</styled-content> in 22q11.2<styled-content style="fixed-case">DS</styled-content>. <styled-content style="fixed-case">DCD</styled-content>, developmental coordination disorder, <styled-content style="fixed-case">ADHD</styled-content>, attention‐deficit/hyperactivity disorder, <styled-content style="fixed-case">ASD</styled-content>, autism spectrum disorder; DCD, developmental coordination disorder</p>
</caption>
<graphic id="nlm-graphic-1" xlink:href="EPI-60-818-g001"></graphic>
</fig>
</sec>
</sec>
</sec>
<sec id="epi14722-sec-0023">
<label>4</label>
<title>DISCUSSION</title>
<p>We showed that 11.1% of deletion carriers screened positive for an epilepsy diagnosis, a rate that falls within the wide‐ranging prevalence estimates from previous studies (4.4%‐36.8%<xref ref-type="ref" rid="epi14722-bib-0009">9</xref>, <xref ref-type="ref" rid="epi14722-bib-0013">13</xref>, <xref ref-type="ref" rid="epi14722-bib-0014">14</xref>, <xref ref-type="ref" rid="epi14722-bib-0015">15</xref>, <xref ref-type="ref" rid="epi14722-bib-0017">17</xref>, <xref ref-type="ref" rid="epi14722-bib-0018">18</xref>). Over half of deletion carriers were, however, reported to have seizures or seizurelike symptoms without a diagnosis. In addition, 24.1% were reported to have febrile seizures. Results from a second stage of assessment (interview, prolonged ambulatory EEG, medical records, epileptologist review) indicated that rates of questionnaire‐reported epilepsy and febrile seizures were accurate and highlighted that in some deletion carriers, epileptic seizures may not be recognized during routine clinical care, and an epilepsy diagnosis may be overlooked. Deletion carriers who took part in the second assessment were older than those who did not, because this second assessment was conducted as part of a longitudinal study of development in young people with 22q11.2DS (Chawner et al<xref ref-type="ref" rid="epi14722-bib-0037">37</xref>). Deletion carriers who screened positive on the epilepsy questionnaire had higher rates of ADHD, indicative ASD, indicative DCD, and a lower PIQ. These associations remained significant when cases with an epilepsy diagnosis were excluded, with the exception of ADHD, but none remained significant for febrile seizures. We propose that risk for epileptic seizures in deletion carriers may be symptomatic of underlying aberrant synaptic plasticity and an imbalance in neuronal excitation‐inhibition, also giving rise to impaired cognition, psychopathology, and motor coordination problems.</p>
<sec id="epi14722-sec-0024">
<label>4.1</label>
<title>Epilepsy, seizures, and seizurelike symptoms in young people with 22q11.2DS</title>
<p>We observed an ~60% rate of ESQ‐reported seizures and seizurelike symptoms in deletion carriers, after excluding reported epilepsy cases. These events were more prevalent than in controls and showed many of the same associations with poorer neurodevelopmental outcomes as epilepsy. Our second assessment suggested that half of deletion carriers reported with these events may have had “true” epileptic seizures, mainly febrile and/or unprovoked. Crucially, this assessment also suggested that epileptic seizures may not be recognized during routine clinical care in some deletion carriers. We also newly diagnosed epilepsy in an individual with a clinical history of suspected seizures (nonmotor absences). Our findings are limited somewhat by the “possible” seizure attribution for two deletion carriers, due to remote epileptologist assessment. The ESQ may not detect some deletion carriers with clinically diagnosed epilepsy, as we found for one participant when cross‐referencing with medical records. Ultimately, prospective and systematic study of all ESQ‐reported seizures and seizurelike symptoms, incorporating direct epileptologist assessment, will best address the extent to which epileptic seizures and epilepsy are overlooked in 22q11.2DS.</p>
<sec id="epi14722-sec-0025">
<label>4.1.1</label>
<title>Febrile seizures</title>
<p>Our rate of reported febrile seizures in deletion carriers (24.1%) was higher than previous estimates (2%‐6%).<xref ref-type="ref" rid="epi14722-bib-0012">12</xref>, <xref ref-type="ref" rid="epi14722-bib-0013">13</xref>, <xref ref-type="ref" rid="epi14722-bib-0015">15</xref> This was not explained by the recurrent infections in this syndrome and suggests a reduced seizure threshold, supporting previous findings in adult deletion carriers with psychotropic and hypocalcemia‐induced seizures.<xref ref-type="ref" rid="epi14722-bib-0013">13</xref>
</p>
<p>Febrile seizures in deletion carriers resembled the “simple” phenotype, considered to be relatively benign.<xref ref-type="ref" rid="epi14722-bib-0038">38</xref> Supporting this, ESQ‐reported febrile seizures did not associate with poorer neurodevelopmental outcomes. Future longitudinal studies may better characterize the relationship of febrile seizures with neurodevelopmental trajectories in 22q11.2DS.</p>
</sec>
<sec id="epi14722-sec-0026">
<label>4.1.2</label>
<title>Unprovoked seizures</title>
<p>The median age at onset of unprovoked seizures (33 months) and febrile seizures (14 months) suggests that deletion carriers are at risk for epileptic seizures from early in life. Unprovoked seizures were occurring once a day or more when at their most frequent in 30% of deletion carriers.</p>
</sec>
</sec>
<sec id="epi14722-sec-0027">
<label>4.2</label>
<title>Association of the ESQ with neurodevelopmental problems in 22q11.2DS</title>
<p>The associations of ESQ‐reported epilepsy, seizures, and seizurelike symptoms with impaired cognition, psychopathology, and motor coordination problems in deletion carriers replicate findings from the general population<xref ref-type="ref" rid="epi14722-bib-0039">39</xref>, <xref ref-type="ref" rid="epi14722-bib-0040">40</xref>, <xref ref-type="ref" rid="epi14722-bib-0041">41</xref> and suggest shared neurobiologic risk pathways. One pathway could be aberrant synaptic plasticity and a subsequent imbalance in neuronal excitation‐inhibition. This mechanism associates with both epilepsy and autism.<xref ref-type="ref" rid="epi14722-bib-0042">42</xref> In a mouse model of ASD, aberrant synaptic plasticity was implicated in motor learning deficits via impaired cerebellar long‐term depression response and synaptic pruning.<xref ref-type="ref" rid="epi14722-bib-0043">43</xref> Synaptic plasticity in the prefrontal cortex is important in adolescent development of executive function, a behavioral impairment in ADHD.<xref ref-type="ref" rid="epi14722-bib-0044">44</xref> Impaired hippocampal synaptic plasticity shows links with memory deficits.<xref ref-type="ref" rid="epi14722-bib-0045">45</xref>, <xref ref-type="ref" rid="epi14722-bib-0046">46</xref> Aberrant synaptic plasticity is also implicated in the emergence of the sensory, cognitive, motor, and psychotic features that characterize schizophrenia,<xref ref-type="ref" rid="epi14722-bib-0047">47</xref> for which 22q11.2DS confers risk (22%).<xref ref-type="ref" rid="epi14722-bib-0007">7</xref> Mouse models of 22q11.2DS have demonstrated aberrant synaptic plasticity. For example, hemizygosity for the microRNA biogenesis gene <italic>Dgcr8</italic> leads to enhanced short‐ and long‐term synaptic plasticity within hippocampal CA3‐CA1 synapses, coinciding with spatial memory deficits, as well as enhanced short‐term depression in the prefrontal cortex. Mice that are haploinsufficient for the mitochondrial function gene <italic>Mrpl40</italic> also show abnormal short‐term potentiation within the hippocampus and co‐occurring working memory deficits. The aberrant synaptic plasticity in these mouse models is mediated by dysregulation of presynaptic calcium levels and neurotransmitter release (eg, enhanced glutamate activity).<xref ref-type="ref" rid="epi14722-bib-0045">45</xref>, <xref ref-type="ref" rid="epi14722-bib-0046">46</xref>, <xref ref-type="ref" rid="epi14722-bib-0048">48</xref>
</p>
<p>Epileptic seizures may also cause neurobiologic changes resulting in impaired cognition and ASD‐related behaviors, notably within the hippocampus<xref ref-type="ref" rid="epi14722-bib-0042">42</xref> and may alter cerebral functional organization of motor control.<xref ref-type="ref" rid="epi14722-bib-0049">49</xref> Paroxysmal epileptic activity associates with poorer performance on attention tests.<xref ref-type="ref" rid="epi14722-bib-0050">50</xref> Early life seizures may therefore have deleterious effects on vulnerable neural networks in 22q11.2DS, for example, within hippocampal and prefrontal regions,<xref ref-type="ref" rid="epi14722-bib-0018">18</xref>, <xref ref-type="ref" rid="epi14722-bib-0046">46</xref>, <xref ref-type="ref" rid="epi14722-bib-0048">48</xref> exacerbating impaired cognition, psychopathology, and motor coordination problems. Future longitudinal designs are warranted to assess this hypothesis.</p>
</sec>
<sec id="epi14722-sec-0028">
<label>4.3</label>
<title>Limitations of the Epilepsy Screen Questionnaire, and implications for our findings</title>
<p>The ESQ has high sensitivity for identifying epilepsy patients (96%) and a low false‐positive rate among seizure‐free individuals (7%). However, the estimated positive predictive value (PPV, the proportion of screen‐positive individuals who have epilepsy) in the general population is low (23%, possible range 0%‐100%<xref ref-type="ref" rid="epi14722-bib-0025">25</xref>) reflecting the low prevalence of epilepsy (~1%<xref ref-type="ref" rid="epi14722-bib-0039">39</xref>). The estimated rate of epilepsy in 22q11.2DS is higher (4.4%‐36.8%<xref ref-type="ref" rid="epi14722-bib-0009">9</xref>, <xref ref-type="ref" rid="epi14722-bib-0013">13</xref>, <xref ref-type="ref" rid="epi14722-bib-0014">14</xref>, <xref ref-type="ref" rid="epi14722-bib-0015">15</xref>, <xref ref-type="ref" rid="epi14722-bib-0017">17</xref>, <xref ref-type="ref" rid="epi14722-bib-0018">18</xref>); however, false positives can be expected to occur as a consequence of the complex phenotypic presentation. The results of our second assessment do suggest, however, that most of the ESQ‐reported epilepsy diagnoses were genuine, and that half of deletion carriers reported with seizures or seizurelike symptoms may have had “true” epileptic seizures. Future studies replicating our method should ensure that all individuals with “any positive” take part in the second stage to establish the PPV of the ESQ for epileptic seizures in 22q11.2DS.</p>
</sec>
<sec id="epi14722-sec-0029">
<label>4.4</label>
<title>Clinical implications</title>
<p>Our work reinforces that not only are children with 22q11.2DS at risk of acute symptomatic seizures and epilepsy during the early years of life, but that in some, epileptic seizures may not be recognized during routine clinical care and an epilepsy diagnosis may be overlooked. We recommend a high‐index of suspicion for epileptic seizures in 22q11.2DS, with epileptologist consultation and video‐EEG for uncertain cases. Early intervention for epileptic seizures is important given the associations with poorer neurodevelopmental outcomes. A micro‐chromosomal array should be considered to screen for 22q11.2DS in children presenting with epileptic seizures and congenital heart disease, palatal abnormalities, hypocalcemia, ID, psychopathology, or motor coordination deficits.</p>
<p>In conclusion, we demonstrated that ~60% of young people with 22q11.2DS screen positive for seizures and seizurelike symptoms in the absence of an epilepsy diagnosis. Systematic investigation of a subsample showed that epileptic seizures may not be recognized during routine clinical care and that an epilepsy diagnosis may be overlooked. Risk for epileptic seizures in 22q11.2DS may be symptomatic of aberrant synaptic plasticity and an imbalance in neuronal excitation‐inhibition, also leading to cognitive impairment, psychopathology, and motor coordination problems. We observed a high rate of febrile seizures (24.1%), which provides further evidence for a reduced seizure threshold in 22q11.2DS. Highlighting the prevalence of epileptic seizures and epilepsy and their relationship with neurodevelopment in 22q11.2DS could allow focused intervention by clinicians, ultimately improving outcomes in this syndrome.</p>
</sec>
</sec>
<sec id="epi14722-sec-0031" sec-type="COI-statement">
<title>DISCLOSURE OF CONFLICTS OF INTEREST</title>
<p>Ullrich Bartsch declares funding from Eli Lilly, and Rhys Thomas and Khalid Hamandi declare honoraria from Eisai, Sanofi, and UCB Pharma. The remaining authors have no conflicts of interest to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material content-type="local-data" id="epi14722-sup-0001">
<caption>
<p> </p>
</caption>
<media xlink:href="EPI-60-818-s001.tiff">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="epi14722-sup-0002">
<caption>
<p> </p>
</caption>
<media xlink:href="EPI-60-818-s002.pdf">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</sec>
</body>
<back>
<ack id="epi14722-sec-0030">
<title>ACKNOWLEDGMENTS</title>
<p>We are extremely grateful to the families that took part, and to our funding bodies. We would like to thank Dr. Samuel Chawner, Dr. Sarah Knott, Hayley Moss, and Dr. Hayley Moulding for contributing. We would like to thank the MRC CNGG Core Technical Team for genotyping our sample.</p>
</ack>
<ref-list content-type="cited-references" id="epi14722-bibl-0001">
<title>REFERENCES</title>
<ref id="epi14722-bib-0001">
<label>1</label>
<mixed-citation id="epi14722-cit-0001" publication-type="journal">
<string-name>
<surname>Fung</surname>
<given-names>WL</given-names>
</string-name>, <string-name>
<surname>Butcher</surname>
<given-names>NJ</given-names>
</string-name>, <string-name>
<surname>Costain</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Andrade</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Boot</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Chow</surname>
<given-names>EW</given-names>
</string-name>, et al. <article-title>Practical guidelines for managing adults with 22q11. 2 deletion syndrome</article-title>. <source xml:lang="en"/>Genet Med
<year>2015</year>;<volume>17</volume>:<fpage>599</fpage>.<pub-id pub-id-type="pmid">25569435</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0002">
<label>2</label>
<mixed-citation id="epi14722-cit-0002" publication-type="journal">
<string-name>
<surname>Guna</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Butcher</surname>
<given-names>NJ</given-names>
</string-name>, <string-name>
<surname>Bassett</surname>
<given-names>AS</given-names>
</string-name>. <article-title>Comparative mapping of the 22q11. 2 deletion region and the potential of simple model organisms</article-title>. <source xml:lang="en"/>J Neurodev Disord
<year>2015</year>;<volume>7</volume>:<fpage>18</fpage>.<pub-id pub-id-type="pmid">26137170</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0003">
<label>3</label>
<mixed-citation id="epi14722-cit-0003" publication-type="journal">
<string-name>
<surname>McDonald‐McGinn</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Sullivan</surname>
<given-names>KE</given-names>
</string-name>, <string-name>
<surname>Marino</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Philip</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Swillen</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Vorstman</surname>
<given-names>JA</given-names>
</string-name>, et al. <article-title>22q11. 2 deletion syndrome</article-title>. <source xml:lang="en"/>Nat Rev Dis Primers. <year>2015</year>;<volume>1</volume>:<fpage>15071</fpage>.<pub-id pub-id-type="pmid">27189754</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0004">
<label>4</label>
<mixed-citation id="epi14722-cit-0004" publication-type="journal">
<string-name>
<surname>Cunningham</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Delport</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Cumines</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Busse</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Linden</surname>
<given-names>DEJ</given-names>
</string-name>, <string-name>
<surname>Hall</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Developmental coordination disorder, psychopathology and IQ in 22q11. 2 deletion syndrome</article-title>. <source xml:lang="en"/>Br J Psychiatry
<year>2018</year>;<volume>212</volume>:<fpage>27</fpage>–<lpage>33</lpage>.<pub-id pub-id-type="pmid">29433607</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0005">
<label>5</label>
<mixed-citation id="epi14722-cit-0005" publication-type="journal">
<string-name>
<surname>Schneider</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Debbané</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bassett</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Chow</surname>
<given-names>EW</given-names>
</string-name>, <string-name>
<surname>Fung</surname>
<given-names>WL</given-names>
</string-name>, <string-name>
<surname>van den Bree</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Psychiatric disorders from childhood to adulthood in 22q11. 2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11. 2 Deletion Syndrome</article-title>. <source xml:lang="en"/>Am J Psychiatry
<year>2014</year>;<volume>171</volume>:<fpage>627</fpage>–<lpage>39</lpage>.<pub-id pub-id-type="pmid">24577245</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0006">
<label>6</label>
<mixed-citation id="epi14722-cit-0006" publication-type="journal">
<string-name>
<surname>Niarchou</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Zammit</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>van Goozen</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Thapar</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tierling</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Owen</surname>
<given-names>MJ</given-names>
</string-name>, et al. <article-title>Psychopathology and cognition in children with 22q11. 2 deletion syndrome</article-title>. <source xml:lang="en"/>Br J Psychiatry
<year>2014</year>;<volume>204</volume>:<fpage>46</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="pmid">24115343</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0007">
<label>7</label>
<mixed-citation id="epi14722-cit-0007" publication-type="journal">
<string-name>
<surname>Monks</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Niarchou</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Davies</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Walters</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Williams</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Owen</surname>
<given-names>MJ</given-names>
</string-name>, et al. <article-title>Further evidence for high rates of schizophrenia in 22q11. 2 deletion syndrome</article-title>. <source xml:lang="en"/>Schizophr Res
<year>2014</year>;<volume>153</volume>:<fpage>231</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">24534796</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0008">
<label>8</label>
<mixed-citation id="epi14722-cit-0008" publication-type="journal">
<string-name>
<surname>Niarchou</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Martin</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Thapar</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Owen</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>van den Bree</surname>
<given-names>MB</given-names>
</string-name>. <article-title>The clinical presentation of attention deficit‐hyperactivity disorder (ADHD) in children with 22q11. 2 deletion syndrome</article-title>. <source xml:lang="en"/>Am J Med Genet B Neuropsychiatr Genet
<year>2015</year>;<volume>168</volume>:<fpage>730</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">26400629</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0009">
<label>9</label>
<mixed-citation id="epi14722-cit-0009" publication-type="journal">
<string-name>
<surname>Olsen</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Sparsø</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Weinsheimer</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Dos Santos</surname>
<given-names>MBQ</given-names>
</string-name>, <string-name>
<surname>Mazin</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Rosengren</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Prevalence of rearrangements in the 22q11.2 region and population‐based risk of neuropsychiatric and developmental disorders in a Danish population: a case‐cohort study</article-title>. <source xml:lang="en"/>Lancet Psychiatry. <year>2018</year>;<volume>5</volume>:<fpage>573</fpage>–<lpage>80</lpage>.<pub-id pub-id-type="pmid">29886042</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0010">
<label>10</label>
<mixed-citation id="epi14722-cit-0010" publication-type="journal">
<string-name>
<surname>Swillen</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Devriendt</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Legius</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Eyskens</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Dumoulin</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gewillig</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Intelligence and psychosocial adjustment in velocardiofacial syndrome: a study of 37 children and adolescents with VCFS</article-title>. <source xml:lang="en"/>J Med Genet. <year>1997</year>;<volume>34</volume>:<fpage>453</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">9192263</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0011">
<label>11</label>
<mixed-citation id="epi14722-cit-0011" publication-type="journal">
<string-name>
<surname>De Smedt</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Devriendt</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Fryns</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Vogels</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gewillig</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Swillen</surname>
<given-names>A</given-names>
</string-name>. <article-title>Intellectual abilities in a large sample of children with velo–cardio–facial syndrome: an update</article-title>. <source xml:lang="en"/>J Intellect Disabil Res. <year>2007</year>;<volume>51</volume>:<fpage>666</fpage>–<lpage>70</lpage>.<pub-id pub-id-type="pmid">17845235</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0012">
<label>12</label>
<mixed-citation id="epi14722-cit-0012" publication-type="journal">
<string-name>
<surname>Ryan</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Goodship</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Wilson</surname>
<given-names>DI</given-names>
</string-name>, <string-name>
<surname>Philip</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Levy</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Seidel</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Spectrum of clinical features associated with interstitial chromosome 22q11 deletions: a European collaborative study</article-title>. <source xml:lang="en"/>J Med Genet. <year>1997</year>;<volume>34</volume>:<fpage>798</fpage>–<lpage>804</lpage>.<pub-id pub-id-type="pmid">9350810</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0013">
<label>13</label>
<mixed-citation id="epi14722-cit-0013" publication-type="journal">
<string-name>
<surname>Wither</surname>
<given-names>RG</given-names>
</string-name>, <string-name>
<surname>Borlot</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>MacDonald</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Butcher</surname>
<given-names>NJ</given-names>
</string-name>, <string-name>
<surname>Chow</surname>
<given-names>EWC</given-names>
</string-name>, <string-name>
<surname>Bassett</surname>
<given-names>AS</given-names>
</string-name>, et al. <article-title>22q11. 2 deletion syndrome lowers seizure threshold in adult patients without epilepsy</article-title>. <source xml:lang="en"/>Epilepsia
<year>2017</year>;<volume>58</volume>:<fpage>1095</fpage>–<lpage>101</lpage>.<pub-id pub-id-type="pmid">28448680</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0014">
<label>14</label>
<mixed-citation id="epi14722-cit-0014" publication-type="journal">
<string-name>
<surname>Strehlow</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Swinkels</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Rapps</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Syrbe</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Dorn</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Generalized epilepsy and myoclonic seizures in 22q11. 2 deletion syndrome</article-title>. <source xml:lang="en"/>Mol Syndromol
<year>2016</year>;<volume>7</volume>:<fpage>239</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="pmid">27781034</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0015">
<label>15</label>
<mixed-citation id="epi14722-cit-0015" publication-type="journal">
<string-name>
<surname>Kao</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Mariani</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>McDonald‐McGinn</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Maisenbacher</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>Brooks‐Kayal</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Zackai</surname>
<given-names>EH</given-names>
</string-name>, et al. <article-title>Increased prevalence of unprovoked seizures in patients with a 22q11. 2 deletion</article-title>. <source xml:lang="en"/>Am J Med Genet A
<year>2004</year>;<volume>129</volume>:<fpage>29</fpage>–<lpage>34</lpage>.</mixed-citation>
</ref>
<ref id="epi14722-bib-0016">
<label>16</label>
<mixed-citation id="epi14722-cit-0016" publication-type="journal">
<string-name>
<surname>Cheung</surname>
<given-names>EN</given-names>
</string-name>, <string-name>
<surname>George</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Andrade</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Chow</surname>
<given-names>EW</given-names>
</string-name>, <string-name>
<surname>Silversides</surname>
<given-names>CK</given-names>
</string-name>, <string-name>
<surname>Bassett</surname>
<given-names>AS</given-names>
</string-name>. <article-title>Neonatal hypocalcemia, neonatal seizures, and intellectual disability in 22q11.2 deletion syndrome</article-title>. <source xml:lang="en"/>Genet Med
<year>2014</year>;<volume>16</volume>:<fpage>40</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">23765047</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0017">
<label>17</label>
<mixed-citation id="epi14722-cit-0017" publication-type="journal">
<string-name>
<surname>Kim</surname>
<given-names>EH</given-names>
</string-name>, <string-name>
<surname>Yum</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>BH</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>HW</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>GH</given-names>
</string-name>, et al. <article-title>Epilepsy and Other Neuropsychiatric Manifestations in Children and Adolescents with 22q11. 2 Deletion Syndrome</article-title>. <source xml:lang="en"/>J Clin Neurol
<year>2016</year>;<volume>12</volume>:<fpage>85</fpage>–<lpage>92</lpage>.<pub-id pub-id-type="pmid">26754781</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0018">
<label>18</label>
<mixed-citation id="epi14722-cit-0018" publication-type="journal">
<string-name>
<surname>Andrade</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Krings</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Chow</surname>
<given-names>EW</given-names>
</string-name>, <string-name>
<surname>Kiehl</surname>
<given-names>TR</given-names>
</string-name>, <string-name>
<surname>Bassett</surname>
<given-names>AS</given-names>
</string-name>. <article-title>Hippocampal malrotation is associated with chromosome 22q11. 2 microdeletion</article-title>. <source xml:lang="en"/>Can J Neurol Sci
<year>2013</year>;<volume>40</volume>:<fpage>652</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">23968937</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0019">
<label>19</label>
<mixed-citation id="epi14722-cit-0019" publication-type="journal">
<string-name>
<surname>Mudigoudar</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Nune</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Fulton</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Dayyat</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Wheless</surname>
<given-names>JW</given-names>
</string-name>. <article-title>Epilepsy in 22q11. 2 Deletion Syndrome: a Case Series and Literature Review</article-title>. <source xml:lang="en"/>Pediatr Neurol. <year>2017</year>;<volume>76</volume>:<fpage>86</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="pmid">28969878</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0020">
<label>20</label>
<mixed-citation id="epi14722-cit-0020" publication-type="journal">
<string-name>
<surname>Lal</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Ruppert</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Trucks</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Schulz</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>de Kovel</surname>
<given-names>CG</given-names>
</string-name>, <string-name>
<surname>Kasteleijn‐Nolst Trenité</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Burden Analysis of Rare Microdeletions Suggests a Strong Impact of Neurodevelopmental Genes in Genetic Generalised Epilepsies</article-title>. <source xml:lang="en"/>PLoS Genet. <year>2015</year>;<volume>11</volume>:<fpage>e1005226</fpage>.<pub-id pub-id-type="pmid">25950944</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0021">
<label>21</label>
<mixed-citation id="epi14722-cit-0021" publication-type="journal">
<string-name>
<surname>Pohlmann‐Eden</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Beghi</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Camfield</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Camfield</surname>
<given-names>P</given-names>
</string-name>. <article-title>The first seizure and its management in adults and children</article-title>. <source xml:lang="en"/>BMJ
<year>2006</year>;<volume>332</volume>:<fpage>339</fpage>.<pub-id pub-id-type="pmid">16470055</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0022">
<label>22</label>
<mixed-citation id="epi14722-cit-0022" publication-type="journal">
<string-name>
<surname>Trinka</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Cock</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hesdorffer</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Rossetti</surname>
<given-names>AO</given-names>
</string-name>, <string-name>
<surname>Scheffer</surname>
<given-names>IE</given-names>
</string-name>, <string-name>
<surname>Shinnar</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>A definition and classification of status epilepticus–Report of the ILAE Task Force on Classification of Status Epilepticus</article-title>. <source xml:lang="en"/>Epilepsia. <year>2015</year>;<volume>56</volume>:<fpage>1515</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="pmid">26336950</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0023">
<label>23</label>
<mixed-citation id="epi14722-cit-0023" publication-type="journal">
<string-name>
<surname>Leidy</surname>
<given-names>NK</given-names>
</string-name>, <string-name>
<surname>Elixhauser</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Vickrey</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Means</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Willian</surname>
<given-names>MK</given-names>
</string-name>. <article-title>Seizure frequency and the health‐related quality of life of adults with epilepsy</article-title>. <source xml:lang="en"/>Neurology. <year>1999</year>;<volume>53</volume>:<fpage>162</fpage>–<lpage>162</lpage>.<pub-id pub-id-type="pmid">10408553</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0024">
<label>24</label>
<mixed-citation id="epi14722-cit-0024" publication-type="journal">
<string-name>
<surname>Crockett</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Goudy</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Chinnadurai</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wootten</surname>
<given-names>CT</given-names>
</string-name>. <article-title>Obstructive sleep apnea syndrome in children with 22q11.2 deletion syndrome after operative intervention for velopharyngeal insufficiency</article-title>. <source xml:lang="en"/>Front Pediatr
<year>2014</year>;<volume>2</volume>:<fpage>84</fpage>.<pub-id pub-id-type="pmid">25157342</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0025">
<label>25</label>
<mixed-citation id="epi14722-cit-0025" publication-type="journal">
<string-name>
<surname>Ottman</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Barker‐Cummings</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Leibson</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Vasoli</surname>
<given-names>VM</given-names>
</string-name>, <string-name>
<surname>Hauser</surname>
<given-names>WA</given-names>
</string-name>, <string-name>
<surname>Buchhalter</surname>
<given-names>JR</given-names>
</string-name>. <article-title>Validation of a brief screening instrument for the ascertainment of epilepsy</article-title>. <source xml:lang="en"/>Epilepsia. <year>2010</year>;<volume>51</volume>:<fpage>191</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">19694790</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0026">
<label>26</label>
<mixed-citation id="epi14722-cit-0026" publication-type="journal">
<string-name>
<surname>Ottman</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Hauser</surname>
<given-names>WA</given-names>
</string-name>, <string-name>
<surname>Stallone</surname>
<given-names>L</given-names>
</string-name>. <article-title>Semistructured interview for seizure classification: agreement with physicians’ diagnoses</article-title>. <source xml:lang="en"/>Epilepsia. <year>1990</year>;<volume>31</volume>:<fpage>110</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">2406127</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0027">
<label>27</label>
<mixed-citation id="epi14722-cit-0027" publication-type="journal">
<string-name>
<surname>Ottman</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Hauser</surname>
<given-names>WA</given-names>
</string-name>, <string-name>
<surname>Hong</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hesdorffer</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Schupf</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>Reliability of seizure classification using a semistructured interview</article-title>. <source xml:lang="en"/>Neurology. <year>1993</year>;<volume>43</volume>:<fpage>2526</fpage>–<lpage>2526</lpage>.<pub-id pub-id-type="pmid">8255451</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0028">
<label>28</label>
<mixed-citation id="epi14722-cit-0028" publication-type="journal">
<string-name>
<surname>Fisher</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>van Emde Boas</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Blume</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Elger</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Genton</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE)</article-title>. <source xml:lang="en"/>Epilepsia. <year>2005</year>;<volume>46</volume>:<fpage>470</fpage>–<lpage>2</lpage>.<pub-id pub-id-type="pmid">15816939</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0029">
<label>29</label>
<mixed-citation id="epi14722-cit-0029" publication-type="journal">
<string-name>
<surname>Fisher</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Acevedo</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Arzimanoglou</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bogacz</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Cross</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Elger</surname>
<given-names>CE</given-names>
</string-name>, et al. <article-title>ILAE official report: a practical clinical definition of epilepsy</article-title>. <source xml:lang="en"/>Epilepsia. <year>2014</year>;<volume>55</volume>:<fpage>475</fpage>–<lpage>82</lpage>.<pub-id pub-id-type="pmid">24730690</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0030">
<label>30</label>
<mixed-citation id="epi14722-cit-0030" publication-type="journal">
<string-name>
<surname>Fisher</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Cross</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>French</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Higurashi</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Hirsch</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Jansen</surname>
<given-names>FE</given-names>
</string-name>, et al. <article-title>Operational classification of seizure types by the International League Against Epilepsy: position Paper of the ILAE Commission for Classification and Terminology</article-title>. <source xml:lang="en"/>Epilepsia. <year>2017</year>;<volume>58</volume>:<fpage>522</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">28276060</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0031">
<label>31</label>
<mixed-citation id="epi14722-cit-0031" publication-type="book">
<string-name>
<surname>Weschler</surname>
<given-names>D</given-names>
</string-name>. <source xml:lang="en"/>Weschler abbreviated scale of intelligence (WASI). <publisher-loc>London, UK</publisher-loc>: <publisher-name>Psychological Corporation</publisher-name>; <year>1999</year>.</mixed-citation>
</ref>
<ref id="epi14722-bib-0032">
<label>32</label>
<mixed-citation id="epi14722-cit-0032" publication-type="journal">
<string-name>
<surname>Angold</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Prendergast</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Cox</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Harrington</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Simonoff</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Rutter</surname>
<given-names>M</given-names>
</string-name>. <article-title>The child and adolescent psychiatric assessment (CAPA)</article-title>. <source xml:lang="en"/>Psychol Med. <year>1995</year>;<volume>25</volume>:<fpage>739</fpage>–<lpage>53</lpage>.<pub-id pub-id-type="pmid">7480451</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0033">
<label>33</label>
<mixed-citation id="epi14722-cit-0033" publication-type="book">
<collab collab-type="authors">American Psychiatric Association</collab>
. <source xml:lang="en"/>Diagnostic and statistical manual of mental disorders‐text revision (DSM‐IV‐TR). <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>APA</publisher-name>; <year>2000</year>.</mixed-citation>
</ref>
<ref id="epi14722-bib-0034">
<label>34</label>
<mixed-citation id="epi14722-cit-0034" publication-type="book">
<string-name>
<surname>Rutter</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bailey</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lord</surname>
<given-names>C</given-names>
</string-name>. <source xml:lang="en"/>The social communication questionnaire: manual. <publisher-loc>Torrance, CA</publisher-loc>: <publisher-name>Western Psychological Services</publisher-name>; <year>2003</year>.</mixed-citation>
</ref>
<ref id="epi14722-bib-0035">
<label>35</label>
<mixed-citation id="epi14722-cit-0035" publication-type="journal">
<string-name>
<surname>Wilson</surname>
<given-names>BN</given-names>
</string-name>. <article-title>The developmental coordination disorder questionnaire 2007</article-title>. <source xml:lang="en"/>Phys Occup Ther Pediatr. <year>2012</year>;<volume>29</volume>:<fpage>182</fpage>–<lpage>202</lpage>.</mixed-citation>
</ref>
<ref id="epi14722-bib-0036">
<label>36</label>
<mixed-citation id="epi14722-cit-0036" publication-type="journal">
<string-name>
<surname>Wilson</surname>
<given-names>BN</given-names>
</string-name>, <string-name>
<surname>Kaplan</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Crawford</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Campbell</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Dewey</surname>
<given-names>D</given-names>
</string-name>. <article-title>Reliability and validity of a parent questionnaire on childhood motor skills</article-title>. <source xml:lang="en"/>Am J Occup Ther. <year>2000</year>;<volume>54</volume>:<fpage>484</fpage>–<lpage>93</lpage>.<pub-id pub-id-type="pmid">11006808</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0037">
<label>37</label>
<mixed-citation id="epi14722-cit-0037" publication-type="journal">
<string-name>
<surname>Chawner</surname>
<given-names>SJRA</given-names>
</string-name>, <string-name>
<surname>Doherty</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Moss</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Niarchou</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Walters</surname>
<given-names>JTR</given-names>
</string-name>, <string-name>
<surname>Owen</surname>
<given-names>MJ</given-names>
</string-name>, et al. <article-title>Childhood cognitive development in 22q11. 2 deletion syndrome: case–control study</article-title>. <source xml:lang="en"/>Br J Psychiatry
<year>2017</year>;<volume>211</volume>:<fpage>223</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">28882829</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0038">
<label>38</label>
<mixed-citation id="epi14722-cit-0038" publication-type="journal">
<string-name>
<surname>Graves</surname>
<given-names>RC</given-names>
</string-name>, <string-name>
<surname>Oehler</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Tingle</surname>
<given-names>LE</given-names>
</string-name>. <article-title>Febrile seizures: risks, evaluation, and prognosis</article-title>. <source xml:lang="en"/>Am Fam Physician
<year>2012</year>;<volume>85</volume>:<fpage>149</fpage>–<lpage>53</lpage>.<pub-id pub-id-type="pmid">22335215</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0039">
<label>39</label>
<mixed-citation id="epi14722-cit-0039" publication-type="journal">
<string-name>
<surname>Rai</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Kerr</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>McManus</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Jordanova</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Brugha</surname>
<given-names>TS</given-names>
</string-name>. <article-title>Epilepsy and psychiatric comorbidity: a nationally representative population‐based study</article-title>. <source xml:lang="en"/>Epilepsia. <year>2012</year>;<volume>53</volume>:<fpage>1095</fpage>–<lpage>103</lpage>.<pub-id pub-id-type="pmid">22578079</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0040">
<label>40</label>
<mixed-citation id="epi14722-cit-0040" publication-type="journal">
<string-name>
<surname>Bowley</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kerr</surname>
<given-names>M</given-names>
</string-name>. <article-title>Epilepsy and intellectual disability</article-title>. <source xml:lang="en"/>J Intellect Disabil Res. <year>2000</year>;<volume>44</volume>:<fpage>529</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="pmid">11079350</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0041">
<label>41</label>
<mixed-citation id="epi14722-cit-0041" publication-type="journal">
<string-name>
<surname>Kirby</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Williams</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Koelewijn</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Brindley</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Muthukumaraswamy</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Te Water Naudé</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Benign childhood epilepsy with centrotemporal spikes (BECTS) and developmental co‐ordination disorder</article-title>. <source xml:lang="en"/>Epilepsy Behav
<year>2017</year>;<volume>72</volume>:<fpage>122</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">28575760</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0042">
<label>42</label>
<mixed-citation id="epi14722-cit-0042" publication-type="journal">
<string-name>
<surname>Brooks‐Kayal</surname>
<given-names>A</given-names>
</string-name>. <article-title>Epilepsy and autism spectrum disorders: are there common developmental mechanisms?</article-title>
<source xml:lang="en"/>Brain Dev. <year>2010</year>;<volume>32</volume>:<fpage>731</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">20570072</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0043">
<label>43</label>
<mixed-citation id="epi14722-cit-0043" publication-type="journal">
<string-name>
<surname>Piochon</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kloth</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Grasselli</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Titley</surname>
<given-names>HK</given-names>
</string-name>, <string-name>
<surname>Nakayama</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hashimoto</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Cerebellar Plasticity and Motor Learning Deficits in a Copy Number Variation Mouse Model of Autism</article-title>. <source xml:lang="en"/>Nat Commun. <year>2014</year>;<volume>5</volume>:<fpage>5586</fpage>–<lpage>5586</lpage>.<pub-id pub-id-type="pmid">25418414</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0044">
<label>44</label>
<mixed-citation id="epi14722-cit-0044" publication-type="journal">
<string-name>
<surname>Selemon</surname>
<given-names>LD</given-names>
</string-name>. <article-title>A role for synaptic plasticity in the adolescent development of executive function</article-title>. <source xml:lang="en"/>Transl Psychiatry. <year>2013</year>;<volume>3</volume>:<fpage>e238</fpage>.<pub-id pub-id-type="pmid">23462989</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0045">
<label>45</label>
<mixed-citation id="epi14722-cit-0045" publication-type="journal">
<string-name>
<surname>Devaraju</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Eddins</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Mellado‐Lagarde</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Earls</surname>
<given-names>LR</given-names>
</string-name>, <string-name>
<surname>Westmoreland</surname>
<given-names>JJ</given-names>
</string-name>, et al. <article-title>Haploinsufficiency of the 22q11. 2 microdeletion gene Mrpl40 disrupts short‐term synaptic plasticity and working memory through dysregulation of mitochondrial calcium</article-title>. <source xml:lang="en"/>Mol Psychiatry. <year>2016</year>;<volume>22</volume>:<fpage>1313</fpage>–<lpage>26</lpage>.<pub-id pub-id-type="pmid">27184122</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0046">
<label>46</label>
<mixed-citation id="epi14722-cit-0046" publication-type="journal">
<string-name>
<surname>Earls</surname>
<given-names>LR</given-names>
</string-name>, <string-name>
<surname>Fricke</surname>
<given-names>RG</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Berry</surname>
<given-names>RB</given-names>
</string-name>, <string-name>
<surname>Baldwin</surname>
<given-names>LT</given-names>
</string-name>, <string-name>
<surname>Zakharenko</surname>
<given-names>SS</given-names>
</string-name>. <article-title>Age‐dependent microRNA control of synaptic plasticity in 22q11 deletion syndrome and schizophrenia</article-title>. <source xml:lang="en"/>J Neurosci. <year>2012</year>;<volume>32</volume>:<fpage>14132</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="pmid">23055483</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0047">
<label>47</label>
<mixed-citation id="epi14722-cit-0047" publication-type="journal">
<string-name>
<surname>Forsyth</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>
<given-names>DA</given-names>
</string-name>. <article-title>Mapping the consequences of impaired synaptic plasticity in Schizophrenia through development: an integrative model for diverse clinical features</article-title>. <source xml:lang="en"/>Trends Cogn Sci. <year>2017</year>;<volume>21</volume>:<fpage>760</fpage>–<lpage>78</lpage>.<pub-id pub-id-type="pmid">28754595</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0048">
<label>48</label>
<mixed-citation id="epi14722-cit-0048" publication-type="journal">
<string-name>
<surname>Fenelon</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Mukai</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Hsu</surname>
<given-names>P‐K</given-names>
</string-name>, <string-name>
<surname>Drew</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>Karayiorgou</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Deficiency of Dgcr8, a gene disrupted by the 22q11. 2 microdeletion, results in altered short‐term plasticity in the prefrontal cortex</article-title>. <source xml:lang="en"/>Proc Natl Acad Sci U S A. <year>2011</year>;<volume>108</volume>:<fpage>4447</fpage>–<lpage>52</lpage>.<pub-id pub-id-type="pmid">21368174</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0049">
<label>49</label>
<mixed-citation id="epi14722-cit-0049" publication-type="journal">
<string-name>
<surname>Woodward</surname>
<given-names>KE</given-names>
</string-name>, <string-name>
<surname>Gaxiola‐Valdez</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Mainprize</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Grossi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Goodyear</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>Federico</surname>
<given-names>P</given-names>
</string-name>. <article-title>Recent seizure activity alters motor organization in frontal lobe epilepsy as revealed by task‐based fMRI</article-title>. <source xml:lang="en"/>Epilepsy Res. <year>2014</year>;<volume>108</volume>:<fpage>1286</fpage>–<lpage>98</lpage>.<pub-id pub-id-type="pmid">25052708</pub-id></mixed-citation>
</ref>
<ref id="epi14722-bib-0050">
<label>50</label>
<mixed-citation id="epi14722-cit-0050" publication-type="journal">
<string-name>
<surname>Aldenkamp</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Arends</surname>
<given-names>J</given-names>
</string-name>. <article-title>The relative influence of epileptic EEG discharges, short nonconvulsive seizures, and type of epilepsy on cognitive function</article-title>. <source xml:lang="en"/>Epilepsia. <year>2004</year>;<volume>45</volume>:<fpage>54</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="pmid">14692908</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>